{ "instance": { "hznp-20221231.htm": { "axisCustom": 0, "axisStandard": 43, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 1460, "http://xbrl.sec.gov/dei/2022": 37 }, "contextCount": 572, "dts": { "calculationLink": { "local": [ "hznp-20221231_cal.xml" ] }, "definitionLink": { "local": [ "hznp-20221231_def.xml" ] }, "inline": { "local": [ "hznp-20221231.htm" ] }, "labelLink": { "local": [ "hznp-20221231_lab.xml" ] }, "presentationLink": { "local": [ "hznp-20221231_pre.xml" ] }, "schema": { "local": [ "hznp-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 1130, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 11, "http://www.horizontherapeutics.com/20221231": 1, "http://xbrl.sec.gov/dei/2022": 4, "total": 16 }, "keyCustom": 139, "keyStandard": 515, "memberCustom": 126, "memberStandard": 71, "nsprefix": "hznp", "nsuri": "http://www.horizontherapeutics.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Acquisitions, Divestitures and Other Arrangements", "menuCat": "Notes", "order": "10", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangements", "shortName": "Acquisitions, Divestitures and Other Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_d9537233-a088-4852-bbd5-6c3091513ffb", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101030 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Restricted Stock Unit Activity (Detail)", "menuCat": "Details", "order": "100", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Restricted Stock Unit Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_d9537233-a088-4852-bbd5-6c3091513ffb", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_b211aa21-9bc1-4bdc-a878-957b2acf2641", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101040 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Performance Stock Unit Awards Activity (Detail)", "menuCat": "Details", "order": "101", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Performance Stock Unit Awards Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_b211aa21-9bc1-4bdc-a878-957b2acf2641", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "div", "div", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_cdf445be-c1a7-4241-8f6b-c2ecfe128929", "decimals": "2", "first": true, "lang": null, "name": "hznp:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardPercentageOfNetSalesPerformanceCriteriaMet", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101050 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Performance Stock Unit Awards Activity - (Parenthetical) (Detail)", "menuCat": "Details", "order": "102", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Performance Stock Unit Awards Activity - (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "div", "div", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_cdf445be-c1a7-4241-8f6b-c2ecfe128929", "decimals": "2", "first": true, "lang": null, "name": "hznp:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardPercentageOfNetSalesPerformanceCriteriaMet", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_a75cad08-6441-4b7b-b484-7bea731fa4a9", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101060 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Significant Valuation Assumptions Related to 2022 Relative TSR PSUs (Detail)", "menuCat": "Details", "order": "103", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedAndLongtermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2022RelativeTsrPsusDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Significant Valuation Assumptions Related to 2022 Relative TSR PSUs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_27a593e5-ed9a-48ad-87ee-f1d7c7c93e72", "decimals": "2", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101070 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Stock-Based Compensation Expense (Detail)", "menuCat": "Details", "order": "104", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101080 - Disclosure - Income Taxes - Company's Income Before Expense (Benefit) for Income Taxes by Jurisdiction (Detail)", "menuCat": "Details", "order": "105", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail", "shortName": "Income Taxes - Company's Income Before Expense (Benefit) for Income Taxes by Jurisdiction (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101090 - Disclosure - Income Taxes - Components of Expense (Benefit) for Income Taxes (Detail)", "menuCat": "Details", "order": "106", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail", "shortName": "Income Taxes - Components of Expense (Benefit) for Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_b9178852-a0d2-495b-bcfd-b953de453ad5", "decimals": "-3", "lang": null, "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101100 - Disclosure - Income Taxes - Additional Information (Detail)", "menuCat": "Details", "order": "107", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-5", "lang": null, "name": "hznp:DeferredIncomeTaxBenefitDueToReductionInStateTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101110 - Disclosure - Income Taxes - Reconciliation Between Irish Statutory Income Tax Rate and U.S Federal Statutory Income Tax Rate (Detail)", "menuCat": "Details", "order": "108", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail", "shortName": "Income Taxes - Reconciliation Between Irish Statutory Income Tax Rate and U.S Federal Statutory Income Tax Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "hznp:DeferredTaxAssetsNetOperatingAndCapitalLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101120 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)", "menuCat": "Details", "order": "109", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail", "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "hznp:DeferredTaxAssetsNetOperatingAndCapitalLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Inventories", "menuCat": "Notes", "order": "11", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_31f4254b-7304-49ee-aa8c-b19985352919", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101130 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amounts of Valuation Allowance (Detail)", "menuCat": "Details", "order": "110", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfValuationAllowanceDetail", "shortName": "Income Taxes - Reconciliation of Beginning and Ending Amounts of Valuation Allowance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "lang": null, "name": "hznp:DeferredTaxAssetsValuationAllowanceIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "hznp:ScheduleOfReconciliationOfUncertainTaxPositionsTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_31f4254b-7304-49ee-aa8c-b19985352919", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101140 - Disclosure - Income Taxes - Changes in Uncertain Income Tax Positions (Detail)", "menuCat": "Details", "order": "111", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesChangesInUncertainIncomeTaxPositionsDetail", "shortName": "Income Taxes - Changes in Uncertain Income Tax Positions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "hznp:ScheduleOfReconciliationOfUncertainTaxPositionsTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_7b314bd7-3274-4eb0-86f9-56d36a9a4e74", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_45df1e11-e529-41e4-bfd4-abdef6ac022d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101150 - Disclosure - Employee Benefit Plans - Summary of Changes in Benefit Obligation (Detail)", "menuCat": "Details", "order": "112", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail", "shortName": "Employee Benefit Plans - Summary of Changes in Benefit Obligation (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_3a5644ea-7fcb-45ba-a92c-0b4252b2f1a1", "decimals": "-3", "lang": null, "name": "hznp:DefinedBenefitPlanPriorServiceCostAtInitiationOfPlan", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_97245df6-dfce-4fd4-a87e-77dd25a72336", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanFundedStatusOfPlan", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101160 - Disclosure - Employee Benefit Plans - Additional Information (Detail)", "menuCat": "Details", "order": "113", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail", "shortName": "Employee Benefit Plans - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_97245df6-dfce-4fd4-a87e-77dd25a72336", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanFundedStatusOfPlan", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_97245df6-dfce-4fd4-a87e-77dd25a72336", "decimals": "-3", "first": true, "lang": null, "name": "hznp:PensionAndOtherPostretirementDefinedBenefitPlansAccruedExpensesAndOtherCurrentLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101170 - Disclosure - Employee Benefit Plans - Summary of Amounts Recognized in Consolidated Balance Sheets (Detail)", "menuCat": "Details", "order": "114", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail", "shortName": "Employee Benefit Plans - Summary of Amounts Recognized in Consolidated Balance Sheets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_97245df6-dfce-4fd4-a87e-77dd25a72336", "decimals": "-3", "first": true, "lang": null, "name": "hznp:PensionAndOtherPostretirementDefinedBenefitPlansAccruedExpensesAndOtherCurrentLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_97245df6-dfce-4fd4-a87e-77dd25a72336", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101180 - Disclosure - Employee Benefit Plans - Summary of Amounts Recognized in Accumulated Other Comprehensive Loss (Detail)", "menuCat": "Details", "order": "115", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail", "shortName": "Employee Benefit Plans - Summary of Amounts Recognized in Accumulated Other Comprehensive Loss (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_97245df6-dfce-4fd4-a87e-77dd25a72336", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_97245df6-dfce-4fd4-a87e-77dd25a72336", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101190 - Disclosure - Employee Benefit Plans - Summary of Total Benefit Payments, Which Reflect Expected Future Service, Expected to Be Paid to Plan Participants (Detail)", "menuCat": "Details", "order": "116", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail", "shortName": "Employee Benefit Plans - Summary of Total Benefit Payments, Which Reflect Expected Future Service, Expected to Be Paid to Plan Participants (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_97245df6-dfce-4fd4-a87e-77dd25a72336", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_5d7db6f9-13e1-486c-9497-9c69e1487d5b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101200 - Disclosure - Employee Benefit Plans - Summary of Net Period Benefit Cost Recognized and Amounts Recognized in Other Comprehensive (Income) Loss (Detail)", "menuCat": "Details", "order": "117", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail", "shortName": "Employee Benefit Plans - Summary of Net Period Benefit Cost Recognized and Amounts Recognized in Other Comprehensive (Income) Loss (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_5d7db6f9-13e1-486c-9497-9c69e1487d5b", "decimals": "-3", "lang": null, "name": "us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_97245df6-dfce-4fd4-a87e-77dd25a72336", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101210 - Disclosure - Employee Benefit Plans - Summary of Weighted-Average Assumptions and Health Care Cost Trend Rates Used to Determine Benefit Obligation (Detail)", "menuCat": "Details", "order": "118", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineBenefitObligationDetail", "shortName": "Employee Benefit Plans - Summary of Weighted-Average Assumptions and Health Care Cost Trend Rates Used to Determine Benefit Obligation (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_97245df6-dfce-4fd4-a87e-77dd25a72336", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_5d7db6f9-13e1-486c-9497-9c69e1487d5b", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101220 - Disclosure - Employee Benefit Plans - Summary of Weighted-Average Assumptions and Health Care Cost Trend Rates Used to Determine Net Periodic Benefit Costs (Detail)", "menuCat": "Details", "order": "119", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail", "shortName": "Employee Benefit Plans - Summary of Weighted-Average Assumptions and Health Care Cost Trend Rates Used to Determine Net Periodic Benefit Costs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_5d7db6f9-13e1-486c-9497-9c69e1487d5b", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Prepaid Expenses and Other Current Assets", "menuCat": "Notes", "order": "12", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R120": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_6b72a44b-eda5-4d54-8ec5-a73b5f94fd45", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101230 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Detail)", "menuCat": "Details", "order": "120", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail", "shortName": "Schedule II - Valuation and Qualifying Accounts (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_5dd4698d-d143-4ae9-8888-d4389eda8f2f", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Property, Plant and Equipment", "menuCat": "Notes", "order": "13", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Goodwill and Intangible Assets", "menuCat": "Notes", "order": "14", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Accrued Expenses and Other Current Liabilities", "menuCat": "Notes", "order": "15", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": null }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Accrued Trade Discounts and Rebates", "menuCat": "Notes", "order": "16", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebates", "shortName": "Accrued Trade Discounts and Rebates", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_2317a0d1-5958-49b0-af1f-e40f9821972f", "decimals": null, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Segment and Other Information", "menuCat": "Notes", "order": "17", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformation", "shortName": "Segment and Other Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "18", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Debt Agreements", "menuCat": "Notes", "order": "19", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements", "shortName": "Debt Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Derivative Instruments and Hedging Activities", "menuCat": "Notes", "order": "20", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivities1", "shortName": "Derivative Instruments and Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Lease Obligations", "menuCat": "Notes", "order": "21", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligations", "shortName": "Lease Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "22", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Legal Proceedings", "menuCat": "Notes", "order": "23", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLegalProceedings", "shortName": "Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Shareholders' Equity", "menuCat": "Notes", "order": "24", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Share-Based and Long-Term Incentive Plans", "menuCat": "Notes", "order": "25", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlans", "shortName": "Share-Based and Long-Term Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "26", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Employee Benefit Plans", "menuCat": "Notes", "order": "27", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Schedule II - Valuation and Qualifying Accounts", "menuCat": "Notes", "order": "28", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccounts", "shortName": "Schedule II - Valuation and Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "29", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:PropertyAndEquipmentExpectedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:PropertyAndEquipmentExpectedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Net Income per Share (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables", "shortName": "Net Income per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_15a443bc-04cc-4cfb-a25b-076e5634f1f0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Acquisitions, Divestitures and Other Arrangements (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables", "shortName": "Acquisitions, Divestitures and Other Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_15a443bc-04cc-4cfb-a25b-076e5634f1f0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Inventories (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Property, Plant and Equipment (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_9fcbcbc9-7528-41cc-89d1-cfc71fd6f98a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Goodwill and Intangible Assets (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_9fcbcbc9-7528-41cc-89d1-cfc71fd6f98a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Accrued Trade Discounts and Rebates (Tables)", "menuCat": "Tables", "order": "38", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesTables", "shortName": "Accrued Trade Discounts and Rebates (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_2317a0d1-5958-49b0-af1f-e40f9821972f", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Segment and Other Information (Tables)", "menuCat": "Tables", "order": "39", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationTables", "shortName": "Segment and Other Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Comprehensive Income", "menuCat": "Statements", "order": "4", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "40", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Debt Agreements (Tables)", "menuCat": "Tables", "order": "41", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTables", "shortName": "Debt Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "menuCat": "Tables", "order": "42", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Lease Obligations (Tables)", "menuCat": "Tables", "order": "43", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsTables", "shortName": "Lease Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Share-Based and Long-Term Incentive Plans (Tables)", "menuCat": "Tables", "order": "44", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansTables", "shortName": "Share-Based and Long-Term Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "45", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Employee Benefit Plans (Tables)", "menuCat": "Tables", "order": "46", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansTables", "shortName": "Employee Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_a75cad08-6441-4b7b-b484-7bea731fa4a9", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Basis of Presentation and Business Overview - Additional Information (Detail)", "menuCat": "Details", "order": "47", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "shortName": "Basis of Presentation and Business Overview - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_c48737bd-76e9-4964-a371-73dab3a23e31", "decimals": "2", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_afc70099-426c-441b-8145-dfab528df241", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "U_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "menuCat": "Details", "order": "48", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_31f4254b-7304-49ee-aa8c-b19985352919", "decimals": "2", "lang": null, "name": "hznp:CashDiscountPercent", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "hznp:PropertyAndEquipmentExpectedUsefulLifeTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_ab97de19-92ca-4cd2-8727-c0e862169ffd", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Summary of Significant Accounting Policies - Depreciation and Amortization Periods for Property, Plant and Equipment (Detail)", "menuCat": "Details", "order": "49", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail", "shortName": "Summary of Significant Accounting Policies - Depreciation and Amortization Periods for Property, Plant and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "hznp:PropertyAndEquipmentExpectedUsefulLifeTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_ab97de19-92ca-4cd2-8727-c0e862169ffd", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_7b314bd7-3274-4eb0-86f9-56d36a9a4e74", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Shareholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_7b314bd7-3274-4eb0-86f9-56d36a9a4e74", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Net Income per Share - Basic and Diluted Net Income per Share (Detail)", "menuCat": "Details", "order": "50", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetail", "shortName": "Net Income per Share - Basic and Diluted Net Income per Share (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Net Income per Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Income per Ordinary Share (Detail)", "menuCat": "Details", "order": "51", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "shortName": "Net Income per Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Income per Ordinary Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f0f1bd1e-3d71-49cd-b3f8-58e371425bc7", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Net Income per Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Income per Ordinary Share ( Parenthetical) (Detail)", "menuCat": "Details", "order": "52", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareParentheticalDetail", "shortName": "Net Income per Share - Schedule of Outstanding Securities Excluded from Computation of Diluted Income per Ordinary Share ( Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_4c68cba5-de3f-4c41-91cf-b31a81ec11f9", "decimals": null, "lang": "en-US", "name": "hznp:DebtInstrumentMaturityYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Net Income per Share - Additional Information (Detail)", "menuCat": "Details", "order": "53", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAdditionalInformationDetail", "shortName": "Net Income per Share - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Additional Information (Detail)", "menuCat": "Details", "order": "54", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "shortName": "Acquisitions, Divestitures and Other Arrangements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_28fd1a17-8b3d-4fb1-a603-015a2cf8ff6c", "decimals": "-5", "lang": null, "name": "hznp:MilestoneAndRoyaltyPayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Summary of Fair Values of Assets Acquired (Details)", "menuCat": "Details", "order": "55", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails", "shortName": "Acquisitions, Divestitures and Other Arrangements - Summary of Fair Values of Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_6f36d132-e312-4f0f-a399-e0ac93b84e8a", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f21f0a81-d902-4da2-bf98-9d6fbe97f593", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Schedule of Total Consideration for the Acquisitions (Detail)", "menuCat": "Details", "order": "56", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail", "shortName": "Acquisitions, Divestitures and Other Arrangements - Schedule of Total Consideration for the Acquisitions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f21f0a81-d902-4da2-bf98-9d6fbe97f593", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f21f0a81-d902-4da2-bf98-9d6fbe97f593", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Schedule of Total Consideration for the Acquisitions ((Parenthetical) (Detail)", "menuCat": "Details", "order": "57", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsParentheticalDetail", "shortName": "Acquisitions, Divestitures and Other Arrangements - Schedule of Total Consideration for the Acquisitions ((Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f21f0a81-d902-4da2-bf98-9d6fbe97f593", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Detail)", "menuCat": "Details", "order": "58", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail", "shortName": "Acquisitions, Divestitures and Other Arrangements - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_9cd4f2c8-68d6-4405-8712-329bee4084ee", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Summary Of Pro Forma Combined Results (Detail)", "menuCat": "Details", "order": "59", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfProFormaCombinedResultsDetail", "shortName": "Acquisitions, Divestitures and Other Arrangements - Summary Of Pro Forma Combined Results (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f55dee39-009d-46d4-8b49-5d29c0fcdf0f", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Inventories - Components of Inventories (Detail)", "menuCat": "Details", "order": "60", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoriesDetail", "shortName": "Inventories - Components of Inventories (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Inventories - Additional Information (Detail)", "menuCat": "Details", "order": "61", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "shortName": "Inventories - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_df723c66-3973-4de3-a075-73615a6214ed", "decimals": "-5", "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "hznp:DeferredTaxChargeOnIntraCompanyProfits", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "62", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "lang": null, "name": "us-gaap:AdvancesOnInventoryPurchases", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-5", "first": true, "lang": null, "name": "hznp:IncreaseInDeferredTaxChargeOnIntraCompanyProfits", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Prepaid Expenses and Other Current Assets - Additional Information (Details)", "menuCat": "Details", "order": "63", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails", "shortName": "Prepaid Expenses and Other Current Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-5", "first": true, "lang": null, "name": "hznp:IncreaseInDeferredTaxChargeOnIntraCompanyProfits", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment (Detail)", "menuCat": "Details", "order": "64", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail", "shortName": "Property, Plant and Equipment - Property, Plant and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)", "menuCat": "Details", "order": "65", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail", "shortName": "Property, Plant and Equipment - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_31f4254b-7304-49ee-aa8c-b19985352919", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill for Reportable Segments (Detail)", "menuCat": "Details", "order": "66", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail", "shortName": "Goodwill and Intangible Assets - Schedule of Goodwill for Reportable Segments (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail)", "menuCat": "Details", "order": "67", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "shortName": "Goodwill and Intangible Assets - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-5", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Goodwill and Intangible Assets - Amortizable Intangible Assets (Detail)", "menuCat": "Details", "order": "68", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "shortName": "Goodwill and Intangible Assets - Amortizable Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_2c986287-a436-4a2f-aef8-ac59b7f476b4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Goodwill and Intangible Assets - Amortizable Intangible Assets - (Parenthetical) (Detail)", "menuCat": "Details", "order": "69", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail", "shortName": "Goodwill and Intangible Assets - Amortizable Intangible Assets - (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_0d1ebeb4-5fe1-4c47-b87f-4f595fd7a3a5", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Basis of Presentation and Business Overview", "menuCat": "Notes", "order": "7", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverview", "shortName": "Basis of Presentation and Business Overview", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense (Detail)", "menuCat": "Details", "order": "70", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail", "shortName": "Goodwill and Intangible Assets - Estimated Future Amortization Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "menuCat": "Details", "order": "71", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_31f4254b-7304-49ee-aa8c-b19985352919", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerRefundLiability", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Changes to Refund Liability (Detail)", "menuCat": "Details", "order": "72", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfChangesToRefundLiabilityDetail", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Changes to Refund Liability (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_31f4254b-7304-49ee-aa8c-b19985352919", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerRefundLiability", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_4029281f-d00f-4f40-a2cd-f2d15362cdd9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Accrued Trade Discounts and Rebates - Schedule of Accrued Trade Discounts and Rebates (Detail)", "menuCat": "Details", "order": "73", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "shortName": "Accrued Trade Discounts and Rebates - Schedule of Accrued Trade Discounts and Rebates (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_4029281f-d00f-4f40-a2cd-f2d15362cdd9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "hznp:ScheduleOfCustomerRelatedAccrualsAndAllowancesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_d7cd3fdc-2a17-4e64-ae7c-128eda1dd609", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Accrued Trade Discounts and Rebates - Schedule of Customer-Related Accruals and Allowances (Detail)", "menuCat": "Details", "order": "74", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "shortName": "Accrued Trade Discounts and Rebates - Schedule of Customer-Related Accruals and Allowances (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "hznp:ScheduleOfCustomerRelatedAccrualsAndAllowancesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_d13ce972-ef12-42d5-b964-2772f00c0d57", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_afc70099-426c-441b-8145-dfab528df241", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "U_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Segment and Other Information - Additional Information (Detail)", "menuCat": "Details", "order": "75", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "shortName": "Segment and Other Information - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_9d4c83fd-d5f3-47e7-9cfb-2522d83ac882", "decimals": "2", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Segment and Other Information - Summary of Net Sales by Medicine (Detail)", "menuCat": "Details", "order": "76", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "shortName": "Segment and Other Information - Summary of Net Sales by Medicine (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_a237523b-4c4f-44c0-b4d2-4db36a2c115a", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_cb1dbff3-2f5a-4d50-95f9-c0163c091597", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Segment and Other Information - Summary of Net Sales by Medicine (Parenthetical) (Detail)", "menuCat": "Details", "order": "77", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineParentheticalDetail", "shortName": "Segment and Other Information - Summary of Net Sales by Medicine (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_cb1dbff3-2f5a-4d50-95f9-c0163c091597", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "hznp:RevenueFromContractWithCustomerExcludingAssessedTaxGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Segment and Other Information - Schedule of Gross Sales to Customers Included in Reportable Segments and All Other Customers as a Group (Detail)", "menuCat": "Details", "order": "78", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "shortName": "Segment and Other Information - Schedule of Gross Sales to Customers Included in Reportable Segments and All Other Customers as a Group (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "hznp:RevenueFromContractWithCustomerExcludingAssessedTaxGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100790 - Disclosure - Segment and Other Information - Summary of Net Sales Attributed to Geographic Sources (Detail)", "menuCat": "Details", "order": "79", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "shortName": "Segment and Other Information - Summary of Net Sales Attributed to Geographic Sources (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_5c717ad5-56e0-40a7-8a6c-b8b82f479697", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100800 - Disclosure - Segment and Other Information - Summary of Total Long-Lived Assets by Location (Detail)", "menuCat": "Details", "order": "80", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfTotalLongLivedAssetsByLocationDetail", "shortName": "Segment and Other Information - Summary of Total Long-Lived Assets by Location (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_9103a989-4da2-497a-9daa-55ed0dcfb54a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100810 - Disclosure - Fair Value Measurements - Assets and Liabilities at Fair Value on Recurring Basis (Detail)", "menuCat": "Details", "order": "81", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail", "shortName": "Fair Value Measurements - Assets and Liabilities at Fair Value on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_9103a989-4da2-497a-9daa-55ed0dcfb54a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "INF", "first": true, "lang": null, "name": "hznp:SalesOfEquitySecurities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100830 - Disclosure - Fair Value Measurements - Assets and Liabilities at Fair Value on Recurring Basis (Parenthetical) (Detail)", "menuCat": "Details", "order": "82", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail", "shortName": "Fair Value Measurements - Assets and Liabilities at Fair Value on Recurring Basis (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "INF", "first": true, "lang": null, "name": "hznp:SalesOfEquitySecurities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100840 - Disclosure - Debt Agreements - Outstanding Debt Balances (Detail)", "menuCat": "Details", "order": "83", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "shortName": "Debt Agreements - Outstanding Debt Balances (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100850 - Disclosure - Debt Agreements - Scheduled Maturities of Long-term Debt (Detail)", "menuCat": "Details", "order": "84", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail", "shortName": "Debt Agreements - Scheduled Maturities of Long-term Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100860 - Disclosure - Debt Agreements - Term Loan Facility and Revolving Credit Facility - Additional Information (Detail)", "menuCat": "Details", "order": "85", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "shortName": "Debt Agreements - Term Loan Facility and Revolving Credit Facility - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_35c0bdc4-1c1a-4216-8207-ac061f603ec4", "decimals": "4", "lang": null, "name": "us-gaap:LongTermDebtPercentageBearingVariableInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SeniorLongTermNotes", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100870 - Disclosure - Debt Agreements - 2027 Senior Notes - Additional Information (Detail)", "menuCat": "Details", "order": "86", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "shortName": "Debt Agreements - 2027 Senior Notes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_d020e174-dfe3-4d54-a0c7-896c6f8b7aa2", "decimals": "-5", "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100880 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)", "menuCat": "Details", "order": "87", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "shortName": "Derivative Instruments and Hedging Activities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "INF", "lang": null, "name": "us-gaap:GainLossOnComponentsExcludedFromAssessmentOfForeignCurrencyCashFlowHedgeEffectiveness", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100890 - Disclosure - Derivative Instruments and Hedging Activities - Summery of Amounts and Locations of Derivative Instruments on Condensed Consolidated Balance Sheet (Detail)", "menuCat": "Details", "order": "88", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe", "shortName": "Derivative Instruments and Hedging Activities - Summery of Amounts and Locations of Derivative Instruments on Condensed Consolidated Balance Sheet (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_48cb534b-90be-4828-81d2-86aa9e4c7b9b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100900 - Disclosure - Derivative Instruments and Hedging Activities - Summery of Pre-tax Amount and Locations of Derivative Instrument Net Gains (Losses) Recognized in the Condensed Consolidated Statement of Comprehensive Income (Detail)", "menuCat": "Details", "order": "89", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "shortName": "Derivative Instruments and Hedging Activities - Summery of Pre-tax Amount and Locations of Derivative Instrument Net Gains (Losses) Recognized in the Condensed Consolidated Statement of Comprehensive Income (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_48cb534b-90be-4828-81d2-86aa9e4c7b9b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Net Income per Share", "menuCat": "Notes", "order": "9", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShare1", "shortName": "Net Income per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_ece9fa90-1a3b-4f3f-b4db-4fe33bef4a3c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainOnDerivativeInstrumentsPretax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100910 - Disclosure - Derivative Instruments and Hedging Activities - Summery of Pre-tax Amounts of Gains From Derivative Instruments Recognized in Other Comprehensive Income (Loss) (Detail)", "menuCat": "Details", "order": "90", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco", "shortName": "Derivative Instruments and Hedging Activities - Summery of Pre-tax Amounts of Gains From Derivative Instruments Recognized in Other Comprehensive Income (Loss) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_ece9fa90-1a3b-4f3f-b4db-4fe33bef4a3c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainOnDerivativeInstrumentsPretax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_a423a498-5c0d-4e13-9792-f99a39d9a1cc", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "U_sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100930 - Disclosure - Lease Obligations - Schedule of Office Space Lease Agreements in Place for Real Properties (Detail)", "menuCat": "Details", "order": "91", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "shortName": "Lease Obligations - Schedule of Office Space Lease Agreements in Place for Real Properties (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_a423a498-5c0d-4e13-9792-f99a39d9a1cc", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "U_sqft", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeLeasesPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100940 - Disclosure - Lease Obligations - Additional Information (Detail)", "menuCat": "Details", "order": "92", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "shortName": "Lease Obligations - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100950 - Disclosure - Lease Obligations - Schedule of Lease Liabilities Recorded on the Balance Sheet (Detail)", "menuCat": "Details", "order": "93", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail", "shortName": "Lease Obligations - Schedule of Lease Liabilities Recorded on the Balance Sheet (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentCompanyCommittedCapital", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100960 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "menuCat": "Details", "order": "94", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentCompanyCommittedCapital", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100970 - Disclosure - Shareholders' Equity - Additional Information (Detail)", "menuCat": "Details", "order": "95", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail", "shortName": "Shareholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "-5", "lang": null, "name": "hznp:SharesIssuedDuringPeriodInConnectionWithStockOptionExercisesVestingOfRestrictedStockUnitsAndEmployeeSharePurchasePlanPurchases", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100980 - Disclosure - Share-Based and Long-Term Incentive Plans - Additional Information (Detail)", "menuCat": "Details", "order": "96", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_a75cad08-6441-4b7b-b484-7bea731fa4a9", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100990 - Disclosure - Share-Based and Long-Term Incentive Plans - Estimated Fair Value of Converted Stock Options Using Hull-White Model in Binomial Lattice Option Pricing Framework (Detail)", "menuCat": "Details", "order": "97", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Estimated Fair Value of Converted Stock Options Using Hull-White Model in Binomial Lattice Option Pricing Framework (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_4f40e6cf-1fe2-461e-8d32-814a5617347f", "decimals": "4", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_31f4254b-7304-49ee-aa8c-b19985352919", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101000 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Stock Option Activity (Detail)", "menuCat": "Details", "order": "98", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_03fab202-deb6-405e-8d9d-5c03d7a60c1a", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101010 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Outstanding Stock Options (Detail)", "menuCat": "Details", "order": "99", "role": "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Outstanding Stock Options (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "hznp-20221231.htm", "contextRef": "C_f3069df9-0eb0-46a2-aa53-68337cf56866", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } } }, "segmentCount": 201, "tag": { "country_IE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "Ireland [Member]" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfTotalLongLivedAssetsByLocationDetail" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]", "verboseLabel": "United States [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfTotalLongLivedAssetsByLocationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r907", "r908", "r909" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r907", "r908", "r909" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r907", "r908", "r909" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "verboseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r907", "r908", "r909" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r910" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r905" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r904" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "verboseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r904" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r904" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r911" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r904" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r904" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r904" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r904" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r912" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r907", "r908", "r909" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r903" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r906" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "hznp_AGCBiologicsASMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGC Biologics A/S.", "label": "A G C Biologics A S [Member]", "terseLabel": "AGC Biologics A/S [Member]" } } }, "localname": "AGCBiologicsASMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_AROXDHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ARO XDH Member.", "label": "A R O X D H [Member]", "terseLabel": "AROXDH [Member]" } } }, "localname": "AROXDHMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_AccrualForRebatesAndTradeDiscounts": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrual for rebates and trade discounts.", "label": "Accrual For Rebates And Trade Discounts", "terseLabel": "Accrued trade discounts and rebates" } } }, "localname": "AccrualForRebatesAndTradeDiscounts", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "hznp_AccruedCoPayAndOtherPatientAssistanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Co-pay And Other Patient Assistance.", "label": "Accrued Co Pay And Other Patient Assistance [Member]", "terseLabel": "Accrued Co-Pay and Other Patient Assistance [Member]" } } }, "localname": "AccruedCoPayAndOtherPatientAssistanceMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail" ], "xbrltype": "domainItemType" }, "hznp_AccruedCommercialRebatesAndWholesalerFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued commercial rebates and wholesaler fees.", "label": "Accrued Commercial Rebates And Wholesaler Fees [Member]", "terseLabel": "Accrued Commercial Rebates and Wholesaler Fees [Member]" } } }, "localname": "AccruedCommercialRebatesAndWholesalerFeesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail" ], "xbrltype": "domainItemType" }, "hznp_AccruedExpenseAllowancesForReturns": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expense allowances for returns.", "label": "Accrued Expense Allowances For Returns", "terseLabel": "Allowances for returns" } } }, "localname": "AccruedExpenseAllowancesForReturns", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AccruedGovernmentRebatesAndChargeBacksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Government Rebates And Charge Backs.", "label": "Accrued Government Rebates And Charge Backs [Member]", "terseLabel": "Accrued Government Rebates and Chargebacks [Member]" } } }, "localname": "AccruedGovernmentRebatesAndChargeBacksMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail" ], "xbrltype": "domainItemType" }, "hznp_AccruedLiabilitiesCurrentAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued liabilities current and other current liabilities.", "label": "Accrued Liabilities Current And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrentAndOtherCurrentLiabilities", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "hznp_AccruedResearchAndDevelopmentAndManufacturingPrograms": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development and manufacturing programs.", "label": "Accrued Research And Development And Manufacturing Programs", "terseLabel": "R&D and manufacturing programs" } } }, "localname": "AccruedResearchAndDevelopmentAndManufacturingPrograms", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AccruedTradeDiscountsAndRebatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued trade discounts and rebates.", "label": "Accrued Trade Discounts And Rebates [Member]", "terseLabel": "Accrued Trade Discounts and Rebates [Member]" } } }, "localname": "AccruedTradeDiscountsAndRebatesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebates", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "domainItemType" }, "hznp_AccruedUpfrontAndMilestonePaymentsCurrent": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued upfront and milestone payments current.", "label": "Accrued Upfront And Milestone Payments Current", "terseLabel": "Accrued upfront and milestone payments" } } }, "localname": "AccruedUpfrontAndMilestonePaymentsCurrent", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AcquiredInProcessResearchAndDevelopmentAndMilestoneExpensesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired in-process research and development and milestone expenses.", "label": "Acquired In Process Research and Development and Milestone Expenses Policy Text Block", "terseLabel": "Acquired IPR&D and Milestones Expenses" } } }, "localname": "AcquiredInProcessResearchAndDevelopmentAndMilestoneExpensesPolicyTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hznp_AcquiredInProcessResearchAndDevelopmentAndMilestones": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquired in-process research and development and milestones.", "label": "Acquired in-process research and development and milestones", "terseLabel": "Acquired in-process research and development and milestones" } } }, "localname": "AcquiredInProcessResearchAndDevelopmentAndMilestones", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "hznp_AcquisitionFairValueAtDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition fair value at a discount rate.", "label": "Acquisition Fair Value At Discount Rate", "terseLabel": "Acquisition-date fair value at a discount rate" } } }, "localname": "AcquisitionFairValueAtDiscountRate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_AcquisitionsDivestituresAndOtherArrangementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisitions, divestitures and other arrangements.", "label": "Acquisitions Divestitures And Other Arrangements [Text Block]", "terseLabel": "Acquisitions, Divestitures and Other Arrangements" } } }, "localname": "AcquisitionsDivestituresAndOtherArrangementsTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangements" ], "xbrltype": "textBlockItemType" }, "hznp_ActimmuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ACTIMMUNE.", "label": "Actimmune [Member]", "terseLabel": "ACTIMMUNE Developed Technology [Member]", "verboseLabel": "ACTIMMUNE [Member]" } } }, "localname": "ActimmuneMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_AdditionalDevelopmentAndRegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional development and regulatory milestones.", "label": "Additional Development And Regulatory Milestones [Member]", "terseLabel": "Additional Development and Regulatory Milestones [Member]" } } }, "localname": "AdditionalDevelopmentAndRegulatoryMilestonesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_AdditionalMilestoneBasedDevelopmentFundingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional milestone based development funding.", "label": "Additional Milestone Based Development Funding [Member]", "terseLabel": "Additional Milestone-based Development Funding [Member]" } } }, "localname": "AdditionalMilestoneBasedDevelopmentFundingMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_AdditionalPaymentsContingentOnAchievementOfCertainDevelopmentAndRegulatoryMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional payments contingent on the achievement of certain development and regulatory milestones.", "label": "Additional Payments Contingent On Achievement Of Certain Development And Regulatory Milestones", "terseLabel": "Additional payment to be made upon attainment of milestones", "verboseLabel": "Additional payment to be made upon attainment of development milestones" } } }, "localname": "AdditionalPaymentsContingentOnAchievementOfCertainDevelopmentAndRegulatoryMilestones", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AdditionalPaymentsContingentOnAchievementOfCertainSalesBasedMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional payments contingent on achievement of certain sales based milestones.", "label": "Additional Payments Contingent On Achievement Of Certain Sales Based Milestones", "terseLabel": "Additional payment to be made upon attainment of sales based milestones" } } }, "localname": "AdditionalPaymentsContingentOnAchievementOfCertainSalesBasedMilestones", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AdditionalStagedDevelopmentFundingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional staged development funding.", "label": "Additional Staged Development Funding [Member]" } } }, "localname": "AdditionalStagedDevelopmentFundingMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_AdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustments member", "label": "Adjustments [Member]", "terseLabel": "Adjustments [Member]" } } }, "localname": "AdjustmentsMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "domainItemType" }, "hznp_AfterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "After member", "label": "After [Member]", "terseLabel": "After [Member]", "verboseLabel": "After [Member]" } } }, "localname": "AfterMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "domainItemType" }, "hznp_AggregateDevelopmentMilestonePaymentAmountForNonOrphanIndication": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate development milestone payment amount for non-orphan indication.", "label": "Aggregate Development Milestone Payment Amount For Non Orphan Indication", "terseLabel": "Aggregate development milestone payments amount for non-orphan indication" } } }, "localname": "AggregateDevelopmentMilestonePaymentAmountForNonOrphanIndication", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AggregateDevelopmentMilestonePaymentAmountForOrphanIndication": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate development milestone payment amount for orphan indication.", "label": "Aggregate Development Milestone Payment Amount For Orphan Indication", "terseLabel": "Aggregate development milestone payments amount for orphan indication" } } }, "localname": "AggregateDevelopmentMilestonePaymentAmountForOrphanIndication", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AggregateRegulatoryMilestonePaymentAmountForNonOrphanIndication": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate regulatory milestone payment amount for non-orphan indication.", "label": "Aggregate Regulatory Milestone Payment Amount For Non Orphan Indication", "terseLabel": "Aggregate regulatory milestone payments amount for non-orphan indication" } } }, "localname": "AggregateRegulatoryMilestonePaymentAmountForNonOrphanIndication", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AggregateRegulatoryMilestonePaymentAmountForOrphanIndication": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate regulatory milestone payment amount for orphan indication.", "label": "Aggregate Regulatory Milestone Payment Amount For Orphan Indication", "terseLabel": "Aggregate regulatory milestone payments amount for orphan indication" } } }, "localname": "AggregateRegulatoryMilestonePaymentAmountForOrphanIndication", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AgreementExpiryDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement expiry date.", "label": "Agreement Expiry Date", "terseLabel": "Supply agreement expiry date" } } }, "localname": "AgreementExpiryDate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "hznp_AllowanceForCreditLossesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allowance for credit losses policy.", "label": "Allowance For Credit Losses Policy Policy [Text Block]", "terseLabel": "Allowance for Credit Losses" } } }, "localname": "AllowanceForCreditLossesPolicyPolicyTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hznp_AllowanceForReturnsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allowance for returns.", "label": "Allowance For Returns [Member]", "terseLabel": "Allowance for returns [Member]" } } }, "localname": "AllowanceForReturnsMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" ], "xbrltype": "domainItemType" }, "hznp_AlpineImmuneSciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alpine Immune Sciences, Inc..", "label": "Alpine Immune Sciences Inc [Member]", "terseLabel": "Alpine [Member]" } } }, "localname": "AlpineImmuneSciencesIncMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_AmendedAndRestatedLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and restated license agreement.", "label": "Amended And Restated License Agreement [Member]", "terseLabel": "Amended and Restated License Agreement [Member]" } } }, "localname": "AmendedAndRestatedLicenseAgreementMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ArrowheadPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrowhead pharmaceuticals [Member]", "label": "Arrowhead Pharmaceuticals [Member]", "terseLabel": "Arrowhead Pharmaceuticals [Member]" } } }, "localname": "ArrowheadPharmaceuticalsMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_BUPHENYLDUEXISPENNSAIDTwoPercentagePROCYSBIQUINSAIRRAVICTIRAYOSUPLIZNAAndVIMOVOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BUPHENYL, DUEXIS, PENNSAID 2%, PROCYSBI, QUINSAIR, RAVICTI, RAYOS, UPLIZNA and VIMOVO.", "label": "B U P H E N Y L D U E X I S P E N N S A I D Two Percentage P R O C Y S B I Q U I N S A I R R A V I C T I R A Y O S U P L I Z N A And V I M O V O [Member]", "terseLabel": "BUPHENYL, DUEXIS, PENNSAID 2%, PROCYSBI, QUINSAIR, RAVICTI, RAYOS, UPLIZNA and VIMOVO [Member]" } } }, "localname": "BUPHENYLDUEXISPENNSAIDTwoPercentagePROCYSBIQUINSAIRRAVICTIRAYOSUPLIZNAAndVIMOVOMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_BUPHENYLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BUPHENYL.", "label": "B U P H E N Y L [Member]", "terseLabel": "BUPHENYL [Member]" } } }, "localname": "BUPHENYLMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail" ], "xbrltype": "domainItemType" }, "hznp_BasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis of presentation.", "label": "Basis Of Presentation [Line Items]", "terseLabel": "Basis Of Presentation [Line Items]" } } }, "localname": "BasisOfPresentationLineItems", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_BasisOfPresentationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis of presentation.", "label": "Basis Of Presentation [Table]", "terseLabel": "Basis Of Presentation [Table]" } } }, "localname": "BasisOfPresentationTable", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_BeforeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Before member", "label": "Before [Member]", "terseLabel": "Before [Member]" } } }, "localname": "BeforeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "domainItemType" }, "hznp_BioTechnologyGeneralIsraelLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bio-Technology General (Israel) Ltd.", "label": "Bio Technology General Israel Ltd [Member]", "terseLabel": "Bio-Technology General (Israel) Ltd [Member]" } } }, "localname": "BioTechnologyGeneralIsraelLtdMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_BoehringerIngelheimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boehringer Ingelheim.", "label": "Boehringer Ingelheim [Member]", "terseLabel": "Boehringer Ingelheim [Member]" } } }, "localname": "BoehringerIngelheimMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_BusinessCombinationFairValueAdjustmentToFinishedGoods": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination fair value adjustment to finished goods.", "label": "Business Combination Fair Value Adjustment To Finished Goods", "terseLabel": "Inventory, finished goods, gross" } } }, "localname": "BusinessCombinationFairValueAdjustmentToFinishedGoods", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_BusinessCombinationFairValueAdjustmentToInventoryNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination fair value adjustment to inventory net.", "label": "Business Combination Fair Value Adjustment To Inventory Net", "terseLabel": "Inventories, net" } } }, "localname": "BusinessCombinationFairValueAdjustmentToInventoryNet", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_BusinessCombinationFairValueAdjustmentToInventorySetUpExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination fair value adjustment to inventory set up expense.", "label": "Business Combination Fair Value Adjustment To Inventory Set Up Expense", "terseLabel": "Inventory step-up expense" } } }, "localname": "BusinessCombinationFairValueAdjustmentToInventorySetUpExpense", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_BusinessCombinationFairValueAdjustmentToRawMaterials": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination fair value adjustment to raw materials.", "label": "Business Combination Fair Value Adjustment To Raw Materials", "terseLabel": "Inventory, raw materials" } } }, "localname": "BusinessCombinationFairValueAdjustmentToRawMaterials", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_BusinessCombinationFairValueAdjustmentToWorkInProgress": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination fair value adjustment to work in progress.", "label": "Business Combination Fair Value Adjustment To Work In Progress", "terseLabel": "Inventory, work in Process, gross" } } }, "localname": "BusinessCombinationFairValueAdjustmentToWorkInProgress", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_BusinessCombinationNetSettlementsOnExerciseOfStockOptions": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, net settlements on the exercise of stock options.", "label": "Business Combination Net Settlements On Exercise Of Stock Options", "terseLabel": "Net settlements on the exercise of stock options" } } }, "localname": "BusinessCombinationNetSettlementsOnExerciseOfStockOptions", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_BusinessCombinationProgressPaymentsPaidUnderCollaborationAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination progress payments paid under collaboration agreement.", "label": "Business Combination Progress Payments Paid Under Collaboration Agreement", "verboseLabel": "Business combination progress payments paid under collaboration agreement." } } }, "localname": "BusinessCombinationProgressPaymentsPaidUnderCollaborationAgreement", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedTradeDiscountsAndRebates": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed accrued trade discounts and rebates.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Trade Discounts And Rebates", "negatedLabel": "Accrued trade discounts and rebates" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedTradeDiscountsAndRebates", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "hznp_BusinessCombinationUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination upfront payment.", "label": "Business Combination Upfront Payment", "terseLabel": "Upfront cash payment" } } }, "localname": "BusinessCombinationUpfrontPayment", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_CashAndCashEquivalentsMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents maturity period.", "label": "Cash And Cash Equivalents Maturity Period", "terseLabel": "Cash and cash equivalents maturity period" } } }, "localname": "CashAndCashEquivalentsMaturityPeriod", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "hznp_CashDiscountPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash discount percent.", "label": "Cash Discount Percent", "terseLabel": "Cash discount to incentive for prompt payment" } } }, "localname": "CashDiscountPercent", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_CashFlowHedgeTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash flow hedge terms.", "label": "Cash Flow Hedge Terms", "terseLabel": "Terms of cash flow hedge" } } }, "localname": "CashFlowHedgeTerms", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_CashFlowProjectionsFinancialForecastTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash flow projections financial forecast term.", "label": "Cash Flow Projections Financial Forecast Term", "terseLabel": "Cash flow projections, financial forecast term" } } }, "localname": "CashFlowProjectionsFinancialForecastTerm", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "hznp_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in measurement of operating lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities", "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hznp_CatalentIndianaLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Catalent Indiana LLC.", "label": "Catalent Indiana L L C [Member]", "terseLabel": "Catalent [Member]" } } }, "localname": "CatalentIndianaLLCMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ChangeInEscrowDepositForPropertyPurchase": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in escrow deposit for property purchase.", "label": "Change In Escrow Deposit For Property Purchase", "negatedLabel": "Change in escrow deposit for property purchase" } } }, "localname": "ChangeInEscrowDepositForPropertyPurchase", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hznp_ChicagoOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chicago office.", "label": "Chicago Office [Member]", "terseLabel": "Chicago Office [Member]" } } }, "localname": "ChicagoOfficeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_CoPayAndOtherPatientAssistanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Co-pay and other patient assistance.", "label": "Co Pay And Other Patient Assistance [Member]", "terseLabel": "Co-Pay and Other Patient Assistance [Member]" } } }, "localname": "CoPayAndOtherPatientAssistanceMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "domainItemType" }, "hznp_CommercialRebatesAndWholesalerFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial rebates and wholesaler fees.", "label": "Commercial Rebates And Wholesaler Fees [Member]", "terseLabel": "Commercial Rebates and Wholesaler Fees [Member]" } } }, "localname": "CommercialRebatesAndWholesalerFeesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "domainItemType" }, "hznp_ConsiderationForExchangeOfStockOptions": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Consideration for exchange of stock options.", "label": "Consideration For Exchange Of Stock Options", "terseLabel": "Consideration for exchange of Viela stock options" } } }, "localname": "ConsiderationForExchangeOfStockOptions", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_ContingentConsiderationProceedsFromDivestitures": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contingent consideration proceeds from divestitures.", "label": "Contingent Consideration Proceeds From Divestitures", "terseLabel": "Contingent consideration proceeds from divestiture" } } }, "localname": "ContingentConsiderationProceedsFromDivestitures", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hznp_CosettePharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cosette Pharmaceuticals, Inc.", "label": "Cosette Pharmaceuticals Inc [Member]", "terseLabel": "Cosette Pharmaceuticals, Inc [Member]" } } }, "localname": "CosettePharmaceuticalsIncMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit agreement.", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_CumulativeEffectAdjustmentOnRetainedEarningsNetOfTax1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the cumulative effect on retained earnings net of related income tax effect.", "label": "Cumulative Effect Adjustment On Retained Earnings Net Of Tax1", "terseLabel": "Cumulative effect adjustments from adoption of ASU 2016-02" } } }, "localname": "CumulativeEffectAdjustmentOnRetainedEarningsNetOfTax1", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "hznp_CurzionPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Curzion Pharmaceuticals, Inc.", "label": "Curzion Pharmaceuticals Inc [Member]", "terseLabel": "Curzion Pharmaceuticals Inc [Member]" } } }, "localname": "CurzionPharmaceuticalsIncMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A.", "label": "Customer A [Member]", "terseLabel": "Customer A [Member]" } } }, "localname": "CustomerAMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "hznp_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B.", "label": "Customer B [Member]", "terseLabel": "Customer B [Member]" } } }, "localname": "CustomerBMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "hznp_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C.", "label": "Customer C [Member]", "terseLabel": "Customer C [Member]" } } }, "localname": "CustomerCMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "hznp_CustomerDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer D.", "label": "Customer D [Member]", "terseLabel": "Customer D [Member]" } } }, "localname": "CustomerDMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "hznp_CustomerRelationshipsAndOtherIntangiblesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer relationships and other intangibles.", "label": "Customer Relationships And Other Intangibles [Member]", "terseLabel": "Customer Relationships and Other Intangibles [Member]" } } }, "localname": "CustomerRelationshipsAndOtherIntangiblesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "hznp_DUEXISProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DUEXIS Product.", "label": "D U E X I S Product [Member]", "terseLabel": "DUEXIS [Member]" } } }, "localname": "DUEXISProductMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail" ], "xbrltype": "domainItemType" }, "hznp_DebtInstrumentCovenantComplianceMinimumPercentageOfRevolvingCreditCommitments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, covenant compliance, minimum percentage of revolving credit commitments.", "label": "Debt Instrument Covenant Compliance Minimum Percentage Of Revolving Credit Commitments", "terseLabel": "Minimum percentage of total commitments" } } }, "localname": "DebtInstrumentCovenantComplianceMinimumPercentageOfRevolvingCreditCommitments", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DebtInstrumentLIBORFloorRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument LIBOR floor rate.", "label": "Debt Instrument L I B O R Floor Rate", "terseLabel": "LIBOR floor rate" } } }, "localname": "DebtInstrumentLIBORFloorRate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DebtInstrumentLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument leverage ratio.", "label": "Debt Instrument Leverage Ratio", "terseLabel": "Debt instrument leverage ratio" } } }, "localname": "DebtInstrumentLeverageRatio", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DebtInstrumentMaturityYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument maturity year.", "label": "Debt Instrument Maturity Year", "terseLabel": "Maturity year of debt instrument" } } }, "localname": "DebtInstrumentMaturityYear", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareParentheticalDetail" ], "xbrltype": "gYearItemType" }, "hznp_DebtInstrumentRedemptionInWholeButNotInPartMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument redemption in whole but not in part.", "label": "Debt Instrument Redemption In Whole But Not In Part [Member]", "terseLabel": "After August 1, 2022, in Whole But Not in Part [Member]" } } }, "localname": "DebtInstrumentRedemptionInWholeButNotInPartMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_DebtInstrumentRedemptionPricePercentageOnChangeOfControl": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument redemption price percentage on change of control.", "label": "Debt Instrument Redemption Price Percentage On Change Of Control", "terseLabel": "Redemption price percentage of principal amount of debt instrument on change of control" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOnChangeOfControl", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DebtInstrumentRedemptionSomeOrAllMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument redemption some or all.", "label": "Debt Instrument Redemption Some Or All [Member]", "terseLabel": "Prior to August 1, 2022, Some or All of Aggregate Principal Amount [Member]" } } }, "localname": "DebtInstrumentRedemptionSomeOrAllMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_DebtInstrumentRedemptionUpToFortyPercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument redemption up to forty percent.", "label": "Debt Instrument Redemption Up To Forty Percent [Member]", "terseLabel": "Prior to August 1, 2022 [Member]" } } }, "localname": "DebtInstrumentRedemptionUpToFortyPercentMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_DecreaseInPercentageOnExcessCashFlowForMandatoryPrepaymentsOfDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Decrease in percentage on excess cash flow for mandatory prepayments of debt.", "label": "Decrease In Percentage On Excess Cash Flow For Mandatory Prepayments Of Debt", "terseLabel": "Proceeds from debt issuances, reduction percentage on excess cash flow" } } }, "localname": "DecreaseInPercentageOnExcessCashFlowForMandatoryPrepaymentsOfDebt", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DecreasesToDeferredTaxAssetsValuationAllowancesDueToDivestitureOfBusiness": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decreases to deferred tax assets valuation allowances due to divestiture of business.", "label": "Decreases To Deferred Tax Assets Valuation Allowances Due To Divestiture Of Business", "terseLabel": "Decreases to valuation allowances due to divestiture" } } }, "localname": "DecreasesToDeferredTaxAssetsValuationAllowancesDueToDivestitureOfBusiness", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DeerfieldIllinoisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deerfield, Illinois.", "label": "Deerfield Illinois [Member]", "terseLabel": "Deerfield, Illinois [Member]" } } }, "localname": "DeerfieldIllinoisMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_DeferredFinancingCostsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Financing Costs.", "label": "Deferred Financing Costs Policy Policy [Text Block]", "terseLabel": "Deferred Financing Costs" } } }, "localname": "DeferredFinancingCostsPolicyPolicyTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hznp_DeferredIncomeTaxBenefitDueToReductionInStateTaxRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred income tax benefit due to reduction in state tax rate.", "label": "Deferred Income Tax Benefit Due To Reduction In State Tax Rate", "terseLabel": "Tax benefit recognized due to reduction in state tax rate" } } }, "localname": "DeferredIncomeTaxBenefitDueToReductionInStateTaxRate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DeferredTaxAssetsAccruedExpensesAndReserves": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets Accrued Expenses And Reserves", "label": "Deferred Tax Assets Accrued Expenses And Reserves", "terseLabel": "Accruals and reserves" } } }, "localname": "DeferredTaxAssetsAccruedExpensesAndReserves", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DeferredTaxAssetsIntercompanyInterest": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets intercompany interest.", "label": "Deferred Tax Assets Intercompany Interest", "terseLabel": "Intercompany interest" } } }, "localname": "DeferredTaxAssetsIntercompanyInterest", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DeferredTaxAssetsNetOperatingAndCapitalLossCarryforwards": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets Net Operating And Capital Loss Carryforwards", "label": "Deferred Tax Assets Net Operating And Capital Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsNetOperatingAndCapitalLossCarryforwards", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DeferredTaxAssetsValuationAllowanceIncreaseDecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets valuation allowance increase (decrease).", "label": "Deferred Tax Assets Valuation Allowance Increase Decrease", "negatedLabel": "Increase for year activity" } } }, "localname": "DeferredTaxAssetsValuationAllowanceIncreaseDecrease", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DeferredTaxChargeOnIntraCompanyProfits": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax charge on intra-company profits.", "label": "Deferred Tax Charge On Intra Company Profits", "terseLabel": "Deferred charge for taxes on intercompany profit" } } }, "localname": "DeferredTaxChargeOnIntraCompanyProfits", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hznp_DeferredTaxLiabilitiesInterestRateSwapAsset": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Interest rate swap asset.", "label": "Deferred Tax Liabilities, Interest rate swap asset", "terseLabel": "Interest rate swap asset", "verboseLabel": "Interest rate swap" } } }, "localname": "DeferredTaxLiabilitiesInterestRateSwapAsset", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DeferredTaxLiabilityRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred tax liability rate.", "label": "Deferred Tax Liability Rate", "terseLabel": "Acquisition-date fair value at a discount rate" } } }, "localname": "DeferredTaxLiabilityRate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan accumulated other comprehensive income before tax.", "label": "Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax [Line Items]", "terseLabel": "Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax [Line Items]" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxLineItems", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "hznp_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan accumulated other comprehensive income before tax.", "label": "Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax [Table]", "terseLabel": "Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax [Table]" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxTable", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "hznp_DefinedBenefitPlanAmountsRecognizedInBalanceSheetLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan amounts recognized in balance sheet.", "label": "Defined Benefit Plan Amounts Recognized In Balance Sheet [Line Items]", "terseLabel": "Defined Benefit Plan Amounts Recognized In Balance Sheet [Line Items]" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetLineItems", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail" ], "xbrltype": "stringItemType" }, "hznp_DefinedBenefitPlanAmountsRecognizedInBalanceSheetTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan amounts recognized in balance sheet.", "label": "Defined Benefit Plan Amounts Recognized In Balance Sheet [Table]", "terseLabel": "Defined Benefit Plan Amounts Recognized In Balance Sheet [Table]" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetTable", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail" ], "xbrltype": "stringItemType" }, "hznp_DefinedBenefitPlanExpensesPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan Expenses Paid", "label": "Defined Benefit Plan Expenses Paid", "terseLabel": "Defined benefit plan expenses" } } }, "localname": "DefinedBenefitPlanExpensesPaid", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DefinedBenefitPlanHealthCareCostTrendRatesUsedToDetermineBenefitObligationNextFiscalYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan, health care cost trend rates used to determine benefit obligation, next fiscal year.", "label": "Defined Benefit Plan, Health Care Cost Trend Rates Used to Determine Benefit Obligation, Next Fiscal Year", "terseLabel": "Health care cost trend rate assumed for next year" } } }, "localname": "DefinedBenefitPlanHealthCareCostTrendRatesUsedToDetermineBenefitObligationNextFiscalYear", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineBenefitObligationDetail" ], "xbrltype": "percentItemType" }, "hznp_DefinedBenefitPlanPriorServiceCostAtInitiationOfPlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined benefit plan prior service cost at initiation of plan.", "label": "Defined Benefit Plan Prior Service Cost At Initiation Of Plan", "terseLabel": "Prior service cost at initiation of plan" } } }, "localname": "DefinedBenefitPlanPriorServiceCostAtInitiationOfPlan", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DefinedBenefitPlanUltimateHealthCareCostTrendRateUsedToDetermineBenefitObligation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan, ultimate health care cost trend rate used to determine benefit obligation.", "label": "Defined benefit plan, Ultimate Health Care Cost Trend Rate used to determine benefit obligation", "terseLabel": "Rate to which the cost trend rate is assumed to decline (the \"Ultimate trend rate\")" } } }, "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRateUsedToDetermineBenefitObligation", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineBenefitObligationDetail" ], "xbrltype": "percentItemType" }, "hznp_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRateUsedToDetermineBenefitObligation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan, year health care cost trend rate reaches ultimate trend rate used to determine benefit obligation.", "label": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate Used to Determine Benefit Obligation", "terseLabel": "Year that the rate reaches the ultimate trend rate" } } }, "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRateUsedToDetermineBenefitObligation", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineBenefitObligationDetail" ], "xbrltype": "gYearListItemType" }, "hznp_DerivativeCurrencySettlementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative currency settlement date.", "label": "Derivative Currency Settlement Date", "terseLabel": "Derivative currency settlement date" } } }, "localname": "DerivativeCurrencySettlementDate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_DerivativeForeignCurrencyForwardContractsToPurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative foreign currency forward contracts to purchase.", "label": "Derivative Foreign Currency Forward Contracts To Purchase", "terseLabel": "Derivative foreign currency forward contracts to purchase" } } }, "localname": "DerivativeForeignCurrencyForwardContractsToPurchase", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DerivativeForeignCurrencyForwardContractsToSell": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative foreign currency forward contracts to sell.", "label": "Derivative Foreign Currency Forward Contracts To Sell", "terseLabel": "Derivative foreign currency forward contracts to sell" } } }, "localname": "DerivativeForeignCurrencyForwardContractsToSell", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DevelopmentFundingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development funding.", "label": "Development Funding [Member]" } } }, "localname": "DevelopmentFundingMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_DevelopmentMilestoneRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Development milestone recognized.", "label": "Development Milestone Recognized", "terseLabel": "Development milestone recognized" } } }, "localname": "DevelopmentMilestoneRecognized", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DisposalGroupNotDiscontinuedOperationContingentConsiderationPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group not discontinued operation contingent consideration payment.", "label": "Disposal Group Not Discontinued Operation Contingent Consideration Payment", "verboseLabel": "Potential additional contingent consideration payment" } } }, "localname": "DisposalGroupNotDiscontinuedOperationContingentConsiderationPayment", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DublinOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dublin office.", "label": "Dublin Office [Member]", "terseLabel": "Dublin Office [Member]" } } }, "localname": "DublinOfficeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_DublinOfficeStStephenSGreenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dublin Office St Stephen's Green [Member]", "label": "Dublin Office St Stephen S Green [Member]", "terseLabel": "Dublin Office (St Stephen\u2019s Green) [Member]" } } }, "localname": "DublinOfficeStStephenSGreenMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_DukeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Duke.", "label": "Duke [Member]", "terseLabel": "Duke [Member]" } } }, "localname": "DukeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Line Items]", "terseLabel": "Earnings Per Share [Line Items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_EarningsPerShareTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Table]", "terseLabel": "Earnings Per Share [Table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_EirGenPharmaLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EirGen Pharma Limited.", "label": "Eir Gen Pharma Limited [Member]", "terseLabel": "EirGen Pharma Limited [Member]" } } }, "localname": "EirGenPharmaLimitedMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_EmployeeServiceShareBasedCompensationTaxBenefitDetrimentFromCompensationExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Employee service share based compensation tax benefit (detriment) from compensation expense.", "label": "Employee Service Share Based Compensation Tax Benefit Detriment From Compensation Expense", "terseLabel": "Tax benefit (detriment) recognized from stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitDetrimentFromCompensationExpense", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_EmployeesAndNonexecutiveDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and nonexecutive directors.", "label": "Employees And Nonexecutive Directors [Member]", "terseLabel": "Employees and Nonexecutive Directors [Member]" } } }, "localname": "EmployeesAndNonexecutiveDirectorsMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ExchangeableSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchangeable senior notes.", "label": "Exchangeable Senior Notes [Member]", "terseLabel": "Exchangeable Senior Notes [Member]", "verboseLabel": "2.50% Exchangeable Senior Notes due 2022 [Member]" } } }, "localname": "ExchangeableSeniorNotesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareParentheticalDetail" ], "xbrltype": "domainItemType" }, "hznp_ExpectedAgreementExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected agreement expiration date.", "label": "Expected Agreement Expiration Date", "terseLabel": "Expected early termination period of agreement due to uncertain event" } } }, "localname": "ExpectedAgreementExpirationDate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "hznp_FDAApprovalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FDA approval.", "label": "F D A Approval [Member]", "terseLabel": "FDA Approval [Member]" } } }, "localname": "FDAApprovalMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_FairValueDiscountRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value discount rate percentage.", "label": "Fair Value Discount Rate Percentage", "terseLabel": "Fair value discount rate percentage" } } }, "localname": "FairValueDiscountRatePercentage", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_FederalAndStateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal And State [Member]", "label": "Federal And State [Member]", "terseLabel": "U.S. - Federal and State [Member]" } } }, "localname": "FederalAndStateMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_FederalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal [Member]", "label": "Federal [Member]", "terseLabel": "Federal [Member]" } } }, "localname": "FederalMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_FiniteLivedIntangibleAssetsImpairment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finite-lived intangible assets, impairment.", "label": "Finite Lived Intangible Assets Impairment", "negatedLabel": "Impairment" } } }, "localname": "FiniteLivedIntangibleAssetsImpairment", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_FirstLienLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First lien leverage ratio.", "label": "First Lien Leverage Ratio", "terseLabel": "First lien leverage ratio" } } }, "localname": "FirstLienLeverageRatio", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_ForeignExchangeGainLossAndOtherAdjustments": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Foreign exchange gain loss and other adjustments.", "label": "Foreign Exchange Gain Loss And Other Adjustments", "negatedLabel": "Foreign exchange and other adjustments" } } }, "localname": "ForeignExchangeGainLossAndOtherAdjustments", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hznp_ForeignMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign [Member]", "label": "Foreign [Member]", "terseLabel": "Foreign [Member]" } } }, "localname": "ForeignMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_FourCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four customer.", "label": "Four Customer [Member]", "terseLabel": "Four Customer [Member]" } } }, "localname": "FourCustomerMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_FutureSuccessBasedPaymentsRelatedToDevelopmentRegulatoryAndCommercialMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future success-based payments related to development, regulatory and commercial milestones.", "label": "Future Success Based Payments Related To Development Regulatory And Commercial Milestones", "terseLabel": "Total future success-based payments related to development, regulatory and commercial milestones" } } }, "localname": "FutureSuccessBasedPaymentsRelatedToDevelopmentRegulatoryAndCommercialMilestones", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_GainsLossesOnExtinguishmentOfDebtIncludingCashAndNonCash": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gains losses on extinguishment of debt including cash and non-cash.", "label": "Gains Losses On Extinguishment Of Debt Including Cash And Non Cash", "terseLabel": "Loss on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebtIncludingCashAndNonCash", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "hznp_GaithersburgMarylandOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gaithersburg maryland office.", "label": "Gaithersburg Maryland Office [Member]", "terseLabel": "Gaithersburg Maryland Office [Member]" } } }, "localname": "GaithersburgMarylandOfficeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_GoodwillPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill.", "label": "Goodwill Policy [Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillPolicyTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hznp_GovernmentRebatesAndChargeBacksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government rebates and charge backs.", "label": "Government Rebates And Charge Backs [Member]", "terseLabel": "Government Rebates and Chargebacks [Member]" } } }, "localname": "GovernmentRebatesAndChargeBacksMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "domainItemType" }, "hznp_HalozymesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Halozyme.", "label": "Halozymes [Member]", "terseLabel": "Halozymes [Member]" } } }, "localname": "HalozymesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_HemoShearTherapeuticsLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HemoShear Therapeutics, LLC.", "label": "Hemo Shear Therapeutics Limited Liability Company [Member]", "terseLabel": "HemoShear [Member]" } } }, "localname": "HemoShearTherapeuticsLimitedLiabilityCompanyMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_HorizonPharmaSubsidiariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Horizon Pharma subsidiaries.", "label": "Horizon Pharma Subsidiaries [Member]", "terseLabel": "Horizon Pharma Subsidiaries [Member]" } } }, "localname": "HorizonPharmaSubsidiariesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_HorizonPharmaUSAIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Horizon Pharma USA Inc.", "label": "Horizon Pharma U S A Inc [Member]", "terseLabel": "Horizon Pharma USA Inc [Member]" } } }, "localname": "HorizonPharmaUSAIncMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_HorizonTherapeuticsUSAIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Horizon Therapeutics USA, Inc..", "label": "Horizon Therapeutics U S A Inc [Member]", "terseLabel": "Horizon Therapeutics USA, Inc. [Member]" } } }, "localname": "HorizonTherapeuticsUSAIncMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_HyperionTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hyperion therapeutics Inc.", "label": "Hyperion Therapeutics Inc [Member]", "terseLabel": "Hyperion Therapeutics, Inc. [Member]" } } }, "localname": "HyperionTherapeuticsIncMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_Hzn457Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HZN-457.", "label": "HZN457 [Member]" } } }, "localname": "Hzn457Member", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ImpairmentOfAcquiredInProcessResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment of acquired in process research and development.", "label": "Impairment Of Acquired In Process Research And Development", "terseLabel": "Upfront cash payment" } } }, "localname": "ImpairmentOfAcquiredInProcessResearchAndDevelopment", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxReconciliationChangeInStateEffectiveIncomeTaxRate": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation change in state effective income tax rate.", "label": "Income Tax Reconciliation Change In State Effective Income Tax Rate", "terseLabel": "Change in U.S. state effective tax rate" } } }, "localname": "IncomeTaxReconciliationChangeInStateEffectiveIncomeTaxRate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxReconciliationDisallowedInterest": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation disallowed interest.", "label": "Income Tax Reconciliation Disallowed Interest", "terseLabel": "Disallowed interest" } } }, "localname": "IncomeTaxReconciliationDisallowedInterest", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxReconciliationNotionalInterestDeduction": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income Tax Reconciliation Notional Interest Deduction", "label": "Income Tax Reconciliation Notional Interest Deduction", "negatedLabel": "Notional interest deduction", "verboseLabel": "Tax benefit on Notional interest deduction" } } }, "localname": "IncomeTaxReconciliationNotionalInterestDeduction", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxReconciliationTaxBenefitInJurisdictionWithStatutoryTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation tax benefit in jurisdiction with statutory tax.", "label": "Income Tax Reconciliation Tax Benefit In Jurisdiction With Statutory Tax", "terseLabel": "Tax benefit recognized from jurisdictions with statutory rate" } } }, "localname": "IncomeTaxReconciliationTaxBenefitInJurisdictionWithStatutoryTax", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxReconciliationTaxBenefitOnInterCompanyInventoryTransfer": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation tax benefit on inter company inventory transfer.", "label": "Income Tax Reconciliation Tax Benefit On Inter Company Inventory Transfer", "negatedLabel": "Intercompany inventory transfers" } } }, "localname": "IncomeTaxReconciliationTaxBenefitOnInterCompanyInventoryTransfer", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxReconciliationTaxBenefitOnInterCompanyTransferAndLicenseOfIntellectualPropertyAssets": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 14.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation tax benefit on inter company transfer and license of intellectual property assets.", "label": "Income Tax Reconciliation Tax Benefit On Inter Company Transfer And License Of Intellectual Property Assets", "terseLabel": "Intercompany transfer and license of IP assets" } } }, "localname": "IncomeTaxReconciliationTaxBenefitOnInterCompanyTransferAndLicenseOfIntellectualPropertyAssets", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxReconciliationTaxBenefitOnMovementsInTemporaryDifferenceBetweenBookValueAndTaxBasesOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation tax benefit on movements in temporary difference between book value and tax bases of assets.", "label": "Income Tax Reconciliation Tax Benefit on Movements in Temporary Difference Between Book Value and Tax Bases Of Assets", "terseLabel": "Income tax reconciliation tax benefit of assets" } } }, "localname": "IncomeTaxReconciliationTaxBenefitOnMovementsInTemporaryDifferenceBetweenBookValueAndTaxBasesOfAssets", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxReconciliationTaxBenefitRelatedToDeferredChargesForTaxesOnIntercompanyInventoryTransfers": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation tax benefit related to deferred charges for taxes on intercompany inventory transfers.", "label": "Income Tax Reconciliation Tax Benefit Related To Deferred Charges For Taxes On Intercompany Inventory Transfers", "terseLabel": "Tax benefit related to deferred charges for taxes on intercompany inventory transfers" } } }, "localname": "IncomeTaxReconciliationTaxBenefitRelatedToDeferredChargesForTaxesOnIntercompanyInventoryTransfers", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxReconciliationTaxExpenseOnReversalOfTemporaryDifferenceBetweenBookValueAndTaxBaseOfIntellectualPropertyAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation tax expense on reversal of temporary difference between book value and tax base of intellectual property assets.", "label": "Income Tax Reconciliation Tax Expense On Reversal of Temporary Difference Between Book Value and Tax Base Of Intellectual Property Assets", "terseLabel": "Tax expense recognised on reversal of difference between book value and tax base of intellectual property assets" } } }, "localname": "IncomeTaxReconciliationTaxExpenseOnReversalOfTemporaryDifferenceBetweenBookValueAndTaxBaseOfIntellectualPropertyAssets", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxReconciliationUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation uncertain tax positions.", "label": "Income Tax Reconciliation Uncertain Tax Positions", "terseLabel": "Uncertain tax positions" } } }, "localname": "IncomeTaxReconciliationUncertainTaxPositions", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_IncreaseDecreaseInAccruedTradeDiscountsAndRebates": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued trade discounts and rebates.", "label": "Increase Decrease In Accrued Trade Discounts And Rebates", "terseLabel": "Accrued trade discounts and rebates" } } }, "localname": "IncreaseDecreaseInAccruedTradeDiscountsAndRebates", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hznp_IncreaseInDeferredTaxChargeOnIntraCompanyProfits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase in deferred tax charge on intra company profits.", "label": "Increase in Deferred Tax Charge on Intra Company Profits", "terseLabel": "Increase in deferred tax charge on intra company profits" } } }, "localname": "IncreaseInDeferredTaxChargeOnIntraCompanyProfits", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "hznp_IncreaseInTaxBenefitFromChangeInStateTaxRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase In Tax Benefit From change in state tax rate.", "label": "Increase In Tax Benefit From change in state tax rate", "terseLabel": "Tax expense on change in state tax rate" } } }, "localname": "IncreaseInTaxBenefitFromChangeInStateTaxRate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_IncreaseInTaxBenefitFromImpairmentOfGoodwill": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase in tax benefit from impairment of goodwill.", "label": "Increase in tax benefit from impairment of goodwill", "terseLabel": "Tax expense on impairment of goodwill" } } }, "localname": "IncreaseInTaxBenefitFromImpairmentOfGoodwill", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_InflammationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inflammation member.", "label": "Inflammation [Member]", "terseLabel": "Inflammation [Member]" } } }, "localname": "InflammationMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_InflammationReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inflammation reporting unit.", "label": "Inflammation Reporting Unit [Member]", "terseLabel": "Inflammation Reporting Unit [Member]", "verboseLabel": "Inflammation Reporting Unit" } } }, "localname": "InflammationReportingUnitMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_InventorySetUpExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory set-up expense.", "label": "Inventory Set Up Expense", "terseLabel": "Inventory set-up expense" } } }, "localname": "InventorySetUpExpense", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_InvoicedWholesalerFeesAndCommercialRebatesCoPayAndOtherPatientAssistanceCostsAndGovernmentRebatesAndChargebacksInAccountsPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Invoiced wholesaler fees and commercial rebates, co-pay and other patient assistance costs, and government rebates and chargebacks in accounts payable.", "label": "Invoiced Wholesaler Fees And Commercial Rebates Co Pay And Other Patient Assistance Costs And Government Rebates And Chargebacks In Accounts Payable [Member]", "terseLabel": "Invoiced Commercial Rebates and Wholesaler Fees, Co-Pay and Other Patient Assistance, and Government Rebates and Chargebacks in Accounts Payable [Member]" } } }, "localname": "InvoicedWholesalerFeesAndCommercialRebatesCoPayAndOtherPatientAssistanceCostsAndGovernmentRebatesAndChargebacksInAccountsPayableMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail" ], "xbrltype": "domainItemType" }, "hznp_KRYSTEXXAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KRYSTEXXA.", "label": "K R Y S T E X X A [Member]", "terseLabel": "KRYSTEXXA Developed Technology [Member]", "verboseLabel": "KRYSTEXXA [Member]" } } }, "localname": "KRYSTEXXAMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_KeyExecutiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Key executive.", "label": "Key Executive [Member]", "terseLabel": "Key Executive PSUs [Member]", "verboseLabel": "Key Executive PSUs [Member]" } } }, "localname": "KeyExecutiveMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "hznp_LakeForestOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lake forest office.", "label": "Lake Forest Office [Member]", "terseLabel": "Lake Forest Office [Member]" } } }, "localname": "LakeForestOfficeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_LegalProceedingsRelatedToRAYOSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal proceedings related to RAYOS.", "label": "Legal Proceedings Related To R A Y O S [Member]", "terseLabel": "RAYOS [Member]" } } }, "localname": "LegalProceedingsRelatedToRAYOSMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_LetterOfCreditSubFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Letter of credit sub-facility.", "label": "Letter Of Credit Sub Facility [Member]", "terseLabel": "Letter of Credit Sub-facility [Member]" } } }, "localname": "LetterOfCreditSubFacilityMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement [Member]" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line of credit facility additional borrowing capacity.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of credit facility additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_LineOfCreditFacilityExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility, expiration month and year.", "label": "Line Of Credit Facility Expiration Month And Year", "terseLabel": "Line of credit facility termination period" } } }, "localname": "LineOfCreditFacilityExpirationMonthAndYear", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "hznp_LongTermPurchaseCommitmentAgreementRenewalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long term purchase commitment agreement renewal period.", "label": "Long Term Purchase Commitment Agreement Renewal Period", "terseLabel": "Term of agreement automatically renewal period" } } }, "localname": "LongTermPurchaseCommitmentAgreementRenewalPeriod", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "hznp_LongTermPurchaseCommitmentNoticePeriodForTerminationOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term purchase commitment notice period for termination of agreement.", "label": "Long Term Purchase Commitment Notice Period For Termination Of Agreement", "terseLabel": "Written notice period for termination of agreement" } } }, "localname": "LongTermPurchaseCommitmentNoticePeriodForTerminationOfAgreement", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "hznp_MIGERGOTMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MIGERGOT.", "label": "M I G E R G O T [Member]", "terseLabel": "MIGERGOT [Member]" } } }, "localname": "MIGERGOTMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail" ], "xbrltype": "domainItemType" }, "hznp_MIGERGOTTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MIGERGOT transaction member", "label": "M I G E R G O T Transaction [Member]", "terseLabel": "MIGERGOT Transaction [Member]" } } }, "localname": "MIGERGOTTransactionMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables" ], "xbrltype": "domainItemType" }, "hznp_MVPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MVP.", "label": "M V P [Member]", "terseLabel": "MVP [ Member]" } } }, "localname": "MVPMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_MannheimOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mannheim office.", "label": "Mannheim Office [Member]", "terseLabel": "Mannheim Office [Member]" } } }, "localname": "MannheimOfficeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_MaximumAmountEligibleToReceivePerProgram": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount eligible to receive per program.", "label": "Maximum Amount Eligible To Receive Per Program", "terseLabel": "Maximum amount eligible to receive per program" } } }, "localname": "MaximumAmountEligibleToReceivePerProgram", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_MaximumAmountEntitledToReceiveFromAdditionalDevelopmentAndRegulatoryMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount entitled to receive from additional development and regulatory milestones.", "label": "Maximum Amount Entitled to Receive From Additional Development and Regulatory Milestones", "terseLabel": "Maximum amount entitled to receive from additional development and regulatory milestones" } } }, "localname": "MaximumAmountEntitledToReceiveFromAdditionalDevelopmentAndRegulatoryMilestones", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_MaximumAmountEntitledToReceiveFromSalesBasedMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount entitled to receive from sales-based milestones.", "label": "Maximum Amount Entitled to Receive From Sales-based Milestones", "terseLabel": "Maximum amount entitled to receive from sales-based milestones" } } }, "localname": "MaximumAmountEntitledToReceiveFromSalesBasedMilestones", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_MilestoneAndRoyaltyPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone and royalty payments.", "label": "Milestone And Royalty Payments", "verboseLabel": "Milestone and royalty payments" } } }, "localname": "MilestoneAndRoyaltyPayments", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_MilestoneBasedDevelopmentFundingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone-based development funding.", "label": "Milestone-based development funding [Member]", "terseLabel": "Milestone-based Development Funding [Member]" } } }, "localname": "MilestoneBasedDevelopmentFundingMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_MilestonePaymentReceiveUponEarlierExerciseOfOption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment receive upon earlier exercise of option.", "label": "Milestone Payment Receive Upon Earlier Exercise of Option", "terseLabel": "Milestone payment receive upon earlier exercise of option." } } }, "localname": "MilestonePaymentReceiveUponEarlierExerciseOfOption", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_MilestonePaymentUnderLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment under license agreement.", "label": "Milestone Payment Under License Agreement", "terseLabel": "Milestone incurred" } } }, "localname": "MilestonePaymentUnderLicenseAgreement", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_NetGainsOnPretaxExpectedToReclassifyInToInterestExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net gains on pretax expected to reclassify in to interest expenses.", "label": "Net Gains On Pretax Expected To Reclassify In To Interest Expenses", "terseLabel": "Net gains on pretax expected to reclassify in to interest expenses" } } }, "localname": "NetGainsOnPretaxExpectedToReclassifyInToInterestExpenses", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_NetOperatingLossCarryforwardsBeginsToExpire": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Operating Loss Carryforwards Begins To Expire", "label": "Net Operating Loss Carryforwards Begins To Expire", "terseLabel": "Operating loss carryforward, expiration year" } } }, "localname": "NetOperatingLossCarryforwardsBeginsToExpire", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "hznp_NetSalesThresholdsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net sales thresholds.", "label": "Net Sales Thresholds [Member]", "terseLabel": "Net Sales Thresholds [Member]" } } }, "localname": "NetSalesThresholdsMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_NewIncrementalRevolvingCommitmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Incremental Revolving Commitments.", "label": "New Incremental Revolving Commitments [Member]", "terseLabel": "New Incremental Revolving Commitments [Member]" } } }, "localname": "NewIncrementalRevolvingCommitmentsMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_NonCancellableAdvertisingCommitments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non cancellable advertising commitments", "label": "Non Cancellable Advertising Commitments", "terseLabel": "Advertising commitments" } } }, "localname": "NonCancellableAdvertisingCommitments", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_NovatoOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novato office.", "label": "Novato Office [Member]", "terseLabel": "Novato Office [Member]" } } }, "localname": "NovatoOfficeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeParentheticalDetail" ], "xbrltype": "domainItemType" }, "hznp_NumberOfBuilding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of building.", "label": "Number Of Building", "terseLabel": "Number of building purchased" } } }, "localname": "NumberOfBuilding", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "hznp_NumberOfMajorCustomersAccountedForTradeAccountsReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of major customers accounted for trade accounts receivable.", "label": "Number Of Major Customers Accounted For Trade Accounts Receivable", "terseLabel": "Number of major customers for accounts receivable" } } }, "localname": "NumberOfMajorCustomersAccountedForTradeAccountsReceivable", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "hznp_OpenMarketShareRepurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Open market share repurchases.", "label": "Open market share repurchases [Member]", "terseLabel": "Open Market Share Repurchases [Member]" } } }, "localname": "OpenMarketShareRepurchasesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_OptionToPurchaseCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option To Purchase Common Stock Shares", "label": "Option To Purchase Common Stock Shares", "terseLabel": "Options granted to purchase common stock" } } }, "localname": "OptionToPurchaseCommonStockShares", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "hznp_OrphanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orphan.", "label": "Orphan [Member]", "terseLabel": "Orphan [Member]" } } }, "localname": "OrphanMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_OrphanSegmentNetSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orphan Segment Net Sales.", "label": "Orphan Segment Net Sales [Member]", "terseLabel": "Orphan Segment Net Sales [Member]" } } }, "localname": "OrphanSegmentNetSalesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail" ], "xbrltype": "domainItemType" }, "hznp_OtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other countries.", "label": "Other Countries [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfTotalLongLivedAssetsByLocationDetail" ], "xbrltype": "domainItemType" }, "hznp_OtherCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other customers.", "label": "Other Customers [Member]", "terseLabel": "Other Customers [Member]" } } }, "localname": "OtherCustomersMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "hznp_OtherForeignMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Foreign [Member]", "label": "Other Foreign [Member]", "terseLabel": "Other Foreign [Member]" } } }, "localname": "OtherForeignMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail" ], "xbrltype": "domainItemType" }, "hznp_OtherIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other income expense.", "label": "Other Income Expense [Member]", "terseLabel": "Other (Expense) Income, Net [Member]" } } }, "localname": "OtherIncomeExpenseMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "domainItemType" }, "hznp_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other.", "label": "Other [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "hznp_OtherPrepaidExpensesAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other prepaid expenses and other current assets.", "label": "Other Prepaid Expenses And Other Current Assets", "terseLabel": "Other prepaid expenses and other current assets" } } }, "localname": "OtherPrepaidExpensesAndOtherCurrentAssets", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hznp_PENNSAIDTwoPercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PENNSAID two percent.", "label": "P E N N S A I D Two Percent [Member]", "terseLabel": "PENNSAID 2% [Member]" } } }, "localname": "PENNSAIDTwoPercentMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail" ], "xbrltype": "domainItemType" }, "hznp_PROCYSBIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PROCYSBI.", "label": "P R O C Y S B I [Member]", "terseLabel": "PROCYSBI [Member]", "verboseLabel": "PROCYSBI Developed Technology [Member]" } } }, "localname": "PROCYSBIMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_PatheonPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patheon Pharmaceuticals Inc.", "label": "Patheon Pharmaceuticals Inc [Member]", "terseLabel": "Patheon Pharmaceuticals Inc. [Member]" } } }, "localname": "PatheonPharmaceuticalsIncMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_PaymentForFutureDevelopmentAndSalesThresholds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment for future development and sales thresholds", "label": "Payment For Future Development And Sales Thresholds", "terseLabel": "Maximum payment to be made upon attainment of milestones" } } }, "localname": "PaymentForFutureDevelopmentAndSalesThresholds", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PaymentRelatedToLicenseAndCollaborationAgreements": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment related to license and collaboration agreements.", "label": "Payment Related To License and Collaboration Agreements", "negatedLabel": "Payments related to license and collaboration agreements", "terseLabel": "Payment related to license and collaboration agreements" } } }, "localname": "PaymentRelatedToLicenseAndCollaborationAgreements", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hznp_PensionAndOtherPostretirementDefinedBenefitPlansAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail": { "order": 0.0, "parentTag": "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Pension and other postretirement defined benefit plans accrued expenses and other current liabilities.", "label": "Pension And Other Postretirement Defined Benefit Plans Accrued Expenses And Other Current Liabilities", "negatedLabel": "Accrued expenses and other current liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PensionAndOtherPostretirementDefinedBenefitPlansOtherLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Pension and other postretirement defined benefit plans other long-term liabilities.", "label": "Pension And Other Postretirement Defined Benefit Plans Other Long Term Liabilities", "negatedLabel": "Other long-term liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansOtherLongTermLiabilities", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PercentageOfDebtInstrumentAmortizationOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of debt instrument amortization of principal amount.", "label": "Percentage Of Debt Instrument Amortization Of Principal Amount", "terseLabel": "Percentage of debt instrument amortization of principal amount" } } }, "localname": "PercentageOfDebtInstrumentAmortizationOfPrincipalAmount", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOfNetSalesInEarnOutPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of net sales in earn-out payment.", "label": "Percentage Of Net Sales In Earn Out Payment", "terseLabel": "Percentage of net sales in earn-out payment" } } }, "localname": "PercentageOfNetSalesInEarnOutPayment", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOfRemainingNetObligationsPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining net obligations payments.", "label": "Percentage Of Remaining Net Obligations Payments", "terseLabel": "Percentage of remaining net obligations payments" } } }, "localname": "PercentageOfRemainingNetObligationsPayments", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOfRightToReceivePayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of right to receive payments.", "label": "Percentage Of Right To Receive Payments", "terseLabel": "Percentage of right to receive payments" } } }, "localname": "PercentageOfRightToReceivePayments", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOfRoyaltyOnNetSalesRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty on net sales revenue.", "label": "Percentage Of Royalty On Net Sales Revenue", "terseLabel": "Percentage of royalty on net sales revenue" } } }, "localname": "PercentageOfRoyaltyOnNetSalesRevenue", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOnExcessCashFlowForMandatoryPrepaymentsOfDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage on excess cash flow for mandatory prepayments of debt.", "label": "Percentage On Excess Cash Flow For Mandatory Prepayments Of Debt", "terseLabel": "Proceeds from debt issuances, percentage on excess cash flow" } } }, "localname": "PercentageOnExcessCashFlowForMandatoryPrepaymentsOfDebt", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOnFirstLienLeverageRatioForMandatoryPrepaymentsOfDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage on first lien leverage ratio for mandatory prepayments of debt.", "label": "Percentage On First Lien Leverage Ratio For Mandatory Prepayments Of Debt", "terseLabel": "Proceeds from debt issuances, percentage on first lien leverage ratio" } } }, "localname": "PercentageOnFirstLienLeverageRatioForMandatoryPrepaymentsOfDebt", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preclinical study and clinical trial accruals.", "label": "Preclinical Study And Clinical Trial Accruals Policy [Text Block]", "terseLabel": "Pre-clinical Studies and Clinical Trial Accruals" } } }, "localname": "PreclinicalStudyAndClinicalTrialAccrualsPolicyTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hznp_PremiumPaidForCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Premium paid for common stock.", "label": "Premium Paid For Common Stock [Member]", "terseLabel": "Premium Paid for Common Stock [Member]" } } }, "localname": "PremiumPaidForCommonStockMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "prepaid expenses and other current assets disclosure text block.", "label": "Prepaid Expenses And Other Current Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "hznp_PrepaidIncomeTaxesAndIncomeTaxReceivable": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid income taxes and income tax receivable.", "label": "Prepaid Income Taxes And Income Tax Receivable", "terseLabel": "Prepaid income taxes and income tax receivable" } } }, "localname": "PrepaidIncomeTaxesAndIncomeTaxReceivable", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hznp_PricesReviewLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Prices review liability current.", "label": "Prices Review Liability Current", "terseLabel": "Pricing review liability" } } }, "localname": "PricesReviewLiabilityCurrent", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_ProceedsFromStockOptionExercisesAndVestingOfRestrictedStockUnitsAndEmployeeSharePurchasePlanPurchases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from stock option exercises and vesting of restricted stock units and employee share purchase plan purchases.", "label": "Proceeds From Stock Option Exercises And Vesting Of Restricted Stock Units And Employee Share Purchase Plan Purchases", "terseLabel": "Proceeds from stock option exercises and vesting of restricted stock units and employee share purchase plan purchases" } } }, "localname": "ProceedsFromStockOptionExercisesAndVestingOfRestrictedStockUnitsAndEmployeeSharePurchasePlanPurchases", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PropertyAndEquipmentExpectedUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property And Equipment Expected Useful Life Table [Text Block]", "label": "Property And Equipment Expected Useful Life Table [Text Block]", "terseLabel": "Depreciation and Amortization Periods for Property, Plant and Equipment" } } }, "localname": "PropertyAndEquipmentExpectedUsefulLifeTableTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "hznp_ProvisionsForIncomeTaxExpenseBenefitOnUndistributedEarningsOfSubsidiaries": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provisions for income tax expense benefit on undistributed earnings of subsidiaries.", "label": "Provisions For Income Tax Expense Benefit On Undistributed Earnings Of Subsidiaries", "terseLabel": "Provision for income tax on undistributed earnings of subsidiaries" } } }, "localname": "ProvisionsForIncomeTaxExpenseBenefitOnUndistributedEarningsOfSubsidiaries", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PurchaseAndOtherCommitmentsOutstandingPurchaseOrders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase and other commitments outstanding purchase orders.", "label": "Purchase And Other Commitments Outstanding Purchase Orders", "terseLabel": "Purchase and other commitments outstanding purchase orders" } } }, "localname": "PurchaseAndOtherCommitmentsOutstandingPurchaseOrders", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PurchaseCommitmentOutstandingPurchaseOrders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase commitment outstanding purchase orders.", "label": "Purchase Commitment Outstanding Purchase Orders", "terseLabel": "Purchase commitment outstanding purchase orders" } } }, "localname": "PurchaseCommitmentOutstandingPurchaseOrders", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PurchaseObligationPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase obligation percentage.", "label": "Purchase Obligation Percentage", "terseLabel": "Purchase obligation percentage" } } }, "localname": "PurchaseObligationPercentage", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PurchasesOfAcquiredInProcessResearchAndDevelopmentAndMilestonesIncludedInAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchases of acquired in-process research and development and milestones included in accrued expenses and other current liabilities.", "label": "Purchases Of Acquired In Process Research And Development And Milestones Included In Accrued Expenses And Other Current Liabilities", "terseLabel": "Purchases of acquired in-process research and development and milestones included in accrued expenses and other current liabilities" } } }, "localname": "PurchasesOfAcquiredInProcessResearchAndDevelopmentAndMilestonesIncludedInAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hznp_Q32BioIncCollaborationAndOptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Q32 Bio Inc collaboration and option agreement.", "label": "Q32 Bio Inc Collaboration and Option Agreement [Member]", "terseLabel": "Q32 Bio Inc [Member]" } } }, "localname": "Q32BioIncCollaborationAndOptionAgreementMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_QUINSAIRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "QUINSAIR.", "label": "Q U I N S A I R [Member]", "terseLabel": "QUINSAIR [Member]" } } }, "localname": "QUINSAIRMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail" ], "xbrltype": "domainItemType" }, "hznp_RAVICTIAndBUPHENYLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RAVICTI and BUPHENYL.", "label": "R A V I C T I And B U P H E N Y L [Member]", "terseLabel": "RAVICTI And BUPHENYL [Member]" } } }, "localname": "RAVICTIAndBUPHENYLMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_RAVICTIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RAVICTI.", "label": "R A V I C T I [Member]", "terseLabel": "RAVICTI [Member]" } } }, "localname": "RAVICTIMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail" ], "xbrltype": "domainItemType" }, "hznp_RAYOSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RAYOS.", "label": "R A Y O S [Member]", "terseLabel": "RAYOS [Member]" } } }, "localname": "RAYOSMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail" ], "xbrltype": "domainItemType" }, "hznp_RabbiTrustAssets": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rabbi trust assets.", "label": "Rabbi Trust Assets", "terseLabel": "Rabbi trust assets" } } }, "localname": "RabbiTrustAssets", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hznp_RangeEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range eight.", "label": "Range Eight [Member]", "terseLabel": "Exercise Price Ranges, $42.01 - $81.00 [Member]" } } }, "localname": "RangeEightMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "domainItemType" }, "hznp_RangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range Five [Member]", "label": "Range Five [Member]", "terseLabel": "Exercise Price Ranges, $17.01 - $22.00 [Member]" } } }, "localname": "RangeFiveMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "domainItemType" }, "hznp_RangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range Four [Member]", "label": "Range Four [Member]", "terseLabel": "Exercise Price Ranges, $12.01 - $17.00 [Member]" } } }, "localname": "RangeFourMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "domainItemType" }, "hznp_RangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range One [Member]", "label": "Range One [Member]", "terseLabel": "Exercise Price Ranges, $2.01 - $4.00 [Member]" } } }, "localname": "RangeOneMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "domainItemType" }, "hznp_RangeSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range six.", "label": "Range Seven [Member]", "terseLabel": "Exercise Price Ranges, $28.01 - $36.00 [Member]" } } }, "localname": "RangeSevenMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "domainItemType" }, "hznp_RangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range Six [Member]", "label": "Range Six [Member]", "terseLabel": "Exercise Price Ranges, $22.01 - $28.00 [Member]" } } }, "localname": "RangeSixMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "domainItemType" }, "hznp_RangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range Three [Member]", "label": "Range Three [Member]", "terseLabel": "Exercise Price Ranges, $8.01 - $12.00 [Member]" } } }, "localname": "RangeThreeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "domainItemType" }, "hznp_RangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range Two [Member]", "label": "Range Two [Member]", "terseLabel": "Exercise Price Ranges, $4.01 - $8.00 [Member]" } } }, "localname": "RangeTwoMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "domainItemType" }, "hznp_RavictiBuphenylProcysbiPennsaidTwoPercentDuexisRayosAndQuinsairMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RAVICTI, BUPHENYL,PROCYSBI, PENNSAID 2%,DUEXIS, RAYOS and QUINSAIR.", "label": "Ravicti Buphenyl Procysbi Pennsaid Two Percent Duexis Rayos And Quinsair [Member]", "terseLabel": "RAVICTI, BUPHENYL, PROCYSBI, PENNSAID 2%, DUEXIS, RAYOS and QUINSAIR [Member]" } } }, "localname": "RavictiBuphenylProcysbiPennsaidTwoPercentDuexisRayosAndQuinsairMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ReducedMarginBasedOnLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reduced margin based on leverage ratio.", "label": "Reduced Margin Based On Leverage Ratio", "terseLabel": "Leverage ratio less than applicable margin" } } }, "localname": "ReducedMarginBasedOnLeverageRatio", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_RefinancingLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refinancing loans.", "label": "Refinancing Loans [Member]", "terseLabel": "Refinancing Loans [Member]" } } }, "localname": "RefinancingLoansMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ReleaseOfDeferredTaxAssetsValuationAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Release Of Deferred Tax Assets Valuation Allowance", "label": "Release Of Deferred Tax Assets Valuation Allowance", "terseLabel": "Release of valuation allowances" } } }, "localname": "ReleaseOfDeferredTaxAssetsValuationAllowance", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "hznp_RemeasurementOfRefundLiabilityRecognizedAsRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Remeasurement of refund liability recognized as revenue.", "label": "Remeasurement Of Refund Liability Recognized As Revenue", "terseLabel": "Remeasurement of refund liability recognized as revenue" } } }, "localname": "RemeasurementOfRefundLiabilityRecognizedAsRevenue", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfChangesToRefundLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "hznp_RestrictedStockAwardsVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock awards vesting period.", "label": "Restricted Stock Awards Vesting Period", "terseLabel": "Restricted stock units, vesting period" } } }, "localname": "RestrictedStockAwardsVestingPeriod", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "hznp_RevenueFromContractWithCustomerExcludingAssessedTaxGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from contract with customer excluding assessed tax, gross.", "label": "Revenue From Contract With Customer Excluding Assessed Tax Gross", "terseLabel": "Gross Sales, Amount" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxGross", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "monetaryItemType" }, "hznp_RiverVisionDevelopmentCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "River Vision Development Corp.", "label": "River Vision Development Corp [Member]", "terseLabel": "River Vision [Member]", "verboseLabel": "River Vision [Member]" } } }, "localname": "RiverVisionDevelopmentCorpMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_RocheMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Roche.", "label": "Roche [Member]", "terseLabel": "Roche [Member]" } } }, "localname": "RocheMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_RockvilleMarylandOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rockville maryland office.", "label": "Rockville Maryland Office [Member]", "terseLabel": "Rockville Maryland Office [Member]" } } }, "localname": "RockvilleMarylandOfficeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_RoyaltiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties.", "label": "Royalties Policy [Text Block]", "terseLabel": "Royalties" } } }, "localname": "RoyaltiesPolicyTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hznp_RoyaltyAndEarnoutExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty and earnout expense.", "label": "Royalty and earnout expense" } } }, "localname": "RoyaltyAndEarnoutExpense", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_RoyaltyAndRoyaltyAccretionExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty and royalty accretion expense.", "label": "Royalty And Royalty Accretion Expense", "terseLabel": "Royalty and royalty accretion expense" } } }, "localname": "RoyaltyAndRoyaltyAccretionExpense", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_RoyaltyGuaranteesCommitmentsExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty guarantees commitments expiration date.", "label": "Royalty Guarantees Commitments Expiration Date", "terseLabel": "Royalty commitments expiration date" } } }, "localname": "RoyaltyGuaranteesCommitmentsExpirationDate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "hznp_SROneAndLundbeckfondMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "S.R. One and Lundbeckfond.", "label": "S R One And Lundbeckfond [Member]", "terseLabel": "S R One And Lundbeckfond" } } }, "localname": "SROneAndLundbeckfondMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_SalesBasedMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales based milestones.", "label": "Sales Based Milestones [Member]" } } }, "localname": "SalesBasedMilestonesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_SalesOfEquitySecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales of equity securities.", "label": "Sales Of Equity Securities", "terseLabel": "Sales of equity securities" } } }, "localname": "SalesOfEquitySecurities", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "hznp_SalesRevenueNetMinimumLimitForRoyaltyPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales revenue net minimum limit for royalty payment.", "label": "Sales Revenue Net Minimum Limit For Royalty Payment", "terseLabel": "Net sales minimum limit for royal payment" } } }, "localname": "SalesRevenueNetMinimumLimitForRoyaltyPayment", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_ScheduleOfCustomerRelatedAccrualsAndAllowancesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of customer related accruals and allowances.", "label": "Schedule Of Customer Related Accruals And Allowances Table [Text Block]", "terseLabel": "Schedule of Customer-Related Accruals and Allowances" } } }, "localname": "ScheduleOfCustomerRelatedAccrualsAndAllowancesTableTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "textBlockItemType" }, "hznp_ScheduleOfReconciliationOfUncertainTaxPositionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Reconciliation Of Uncertain Tax Positions Table [Text Block]", "label": "Schedule Of Reconciliation Of Uncertain Tax Positions Table [Text Block]", "terseLabel": "Changes in Uncertain Income Tax Positions" } } }, "localname": "ScheduleOfReconciliationOfUncertainTaxPositionsTableTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "hznp_ScheduleOfShareBasedPaymentAwardPerformanceStockUnitsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share based payment award performance stock units valuation assumptions table text block.", "label": "Schedule Of Share Based Payment Award Performance Stock Units Valuation Assumptions Table [Text Block]", "terseLabel": "Summary of Significant Valuation Assumptions Related to 2022 Relative TSR PSUs" } } }, "localname": "ScheduleOfShareBasedPaymentAwardPerformanceStockUnitsValuationAssumptionsTableTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "hznp_ScheduleOfValuationAllowanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Valuation Allowance Table [Text Block]", "label": "Schedule Of Valuation Allowance Table [Text Block]", "terseLabel": "Reconciliation of Beginning and Ending Amounts of Valuation Allowance" } } }, "localname": "ScheduleOfValuationAllowanceTableTextBlock", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "hznp_SeniorExecutivesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior executives.", "label": "Senior Executives [Member]", "terseLabel": "Senior Executives [Member]" } } }, "localname": "SeniorExecutivesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_SeniorNotesDueTwentyTwentySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior notes due twenty twenty seven.", "label": "Senior Notes Due Twenty Twenty Seven [Member]", "terseLabel": "Senior Notes due 2027 [Member]", "verboseLabel": "Senior Notes due 2027 [Member]" } } }, "localname": "SeniorNotesDueTwentyTwentySevenMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "domainItemType" }, "hznp_SeniorSecuredTermLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured term loans.", "label": "Senior Secured Term Loans [Member]", "terseLabel": "Senior Secured Term Loan [Member]" } } }, "localname": "SeniorSecuredTermLoansMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options forfeited in period average illiquidity discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Average Illiquidity Discount", "terseLabel": "Average Illiquidity discount, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAverageIlliquidityDiscount", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "percentItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodRecordedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options forfeited in period recorded weighted average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Recorded Weighted Average Fair Value", "terseLabel": "Recorded Weighted Average Fair Value Per Unit, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodRecordedWeightedAverageFairValue", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period average illiquidity discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Average Illiquidity Discount", "terseLabel": "Average Illiquidity discount, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAverageIlliquidityDiscount", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "percentItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRecordedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period recorded weighted average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Recorded Weighted Average Fair Value", "terseLabel": "Recorded Weighted Average Fair Value Per Unit, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRecordedWeightedAverageFairValue", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options nonvested average illiquidity discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Average Illiquidity Discount", "periodEndLabel": "Average Illiquidity discount, Outstanding Ending Balance", "periodStartLabel": "Average Illiquidity discount, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAverageIlliquidityDiscount", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "percentItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRecordedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options nonvested recorded weighted average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Recorded Weighted Average Fair Value", "periodEndLabel": "Recorded Weighted Average Fair Value Per Unit, Outstanding Ending Balance", "periodStartLabel": "Recorded Weighted Average Fair Value Per Unit, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRecordedWeightedAverageFairValue", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options performance based adjustment in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Performance Based Adjustment In Period", "terseLabel": "Number of Units, Performance Based Adjustment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriod", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "sharesItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options performance based adjustment in period average illiquidity discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Performance Based Adjustment In Period Average Illiquidity Discount", "terseLabel": "Average Illiquidity discount, Performance Based Adjustment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodAverageIlliquidityDiscount", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "percentItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodRecordedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options performance based adjustment in period recorded weighted average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Performance Based Adjustment In Period Recorded Weighted Average Fair Value", "terseLabel": "Recorded Weighted Average Fair Value Per Unit, Performance Based Adjustment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodRecordedWeightedAverageFairValue", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options performance based adjustment in period weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Performance Based Adjustment In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant-Date Fair Value Per Unit, Performance Based Adjustment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested in period average illiquidity discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Average Illiquidity Discount", "terseLabel": "Average Illiquidity discount, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodAverageIlliquidityDiscount", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "percentItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRecordedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested in period recorded weighted average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Recorded Weighted Average Fair Value", "terseLabel": "Recorded Weighted Average Fair Value Per Unit, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRecordedWeightedAverageFairValue", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquisitionsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award options acquisitions in period weighted average exercise price.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Acquisitions In Period Weighted Average Exercise Price", "terseLabel": "Assumed in acquisition" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquisitionsInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationAwardTrancheFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation award tranche five.", "label": "Share Based Compensation Award Tranche Five [Member]", "terseLabel": "Net Sales PSUs [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheFiveMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ShareBasedCompensationAwardTrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation award tranche four.", "label": "Share Based Compensation Award Tranche Four [Member]", "terseLabel": "Tech Ops PSUs [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheFourMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ShareBasedCompensationAwardTrancheSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation award tranche six.", "label": "Share Based Compensation Award Tranche Six [Member]", "terseLabel": "R&D PSUs [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheSixMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardPercentageOfNetSalesPerformanceCriteriaMet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award award percentage of net sales performance criteria met.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Percentage Of Net Sales Performance Criteria Met", "terseLabel": "Percentage of net sales performance criteria met" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardPercentageOfNetSalesPerformanceCriteriaMet", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "percentItemType" }, "hznp_SharebasedCompensationArrangementBySharebasedPaymentAwardShareReserve": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award share reserve.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Share Reserve", "terseLabel": "Ordinary shares, initial share reserve" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardShareReserve", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "hznp_SharesIssuedDuringPeriodInConnectionWithStockOptionExercisesVestingOfRestrictedStockUnitsAndEmployeeSharePurchasePlanPurchases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued during period in connection with stock option exercises vesting of restricted stock units and employee share purchase plan purchases.", "label": "Shares Issued During Period In Connection With Stock Option Exercises Vesting Of Restricted Stock Units And Employee Share Purchase Plan Purchases", "terseLabel": "Shares issued during period in connection with stock option exercises, vesting of restricted stock units and employee share purchase plan purchases" } } }, "localname": "SharesIssuedDuringPeriodInConnectionWithStockOptionExercisesVestingOfRestrictedStockUnitsAndEmployeeSharePurchasePlanPurchases", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "hznp_Shipments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shipments.", "label": "Shipments", "terseLabel": "Shipments during the year ended December 31, 2022" } } }, "localname": "Shipments", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfChangesToRefundLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "hznp_SouthSanFranciscoOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "South san francisco office.", "label": "South San Francisco Office [Member]", "terseLabel": "South San Francisco Office [Member]" } } }, "localname": "SouthSanFranciscoOfficeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_StockConversionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock conversion rate.", "label": "Stock Conversion Rate", "terseLabel": "Stock Conversion Rate" } } }, "localname": "StockConversionRate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "hznp_SubleaseAgreementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sublease agreement date.", "label": "Sublease Agreement Date", "terseLabel": "Sublease agreement entered date" } } }, "localname": "SubleaseAgreementDate", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "hznp_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "hznp_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "hznp_TEPEZZAAndKRYSTEXXAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TEPEZZA And KRYSTEXXA member", "label": "T E P E Z Z A And K R Y S T E X X A [Member]", "terseLabel": "TEPEZZA And KRYSTEXXA [Member]" } } }, "localname": "TEPEZZAAndKRYSTEXXAMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TEPEZZADevelopedTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TEPEZZA developed technology.", "label": "T E P E Z Z A Developed Technology [Member]", "terseLabel": "T E P E Z Z A Developed Technology" } } }, "localname": "TEPEZZADevelopedTechnologyMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TEPEZZADrugProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TEPEZZA drug product.", "label": "T E P E Z Z A Drug Product [Member]", "terseLabel": "TEPEZZA Drug Product [Member]" } } }, "localname": "TEPEZZADrugProductMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TEPEZZADrugSubstanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TEPEZZA drug member.", "label": "T E P E Z Z A Drug Substance [Member]", "terseLabel": "PROCYSBI API [Member]", "verboseLabel": "TEPEZZA [Member]" } } }, "localname": "TEPEZZADrugSubstanceMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TEPEZZAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TEPEZZA.", "label": "T E P E Z Z A [Member]", "terseLabel": "TEPEZZA [Member]" } } }, "localname": "TEPEZZAMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "hznp_TaxBenefitPartiallyOffsetByTaxExpenseFromShareBasedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax benefit partially offset by tax expense from share based compensation.", "label": "Tax Benefit Partially Offset by Tax Expense From Share Based Compensation", "terseLabel": "Tax expense on non-deductible share-based compensation expenses" } } }, "localname": "TaxBenefitPartiallyOffsetByTaxExpenseFromShareBasedCompensation", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_TeprotumumabMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Teprotumumab.", "label": "Teprotumumab [Member]", "terseLabel": "Teprotumumab [Member]" } } }, "localname": "TeprotumumabMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TermLoanFacilityDueTwentyTwentyEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan facility due twenty twenty eight.", "label": "Term Loan Facility Due Twenty Twenty Eight [Member]", "terseLabel": "2028 Term Loans [Member]", "verboseLabel": "Term Loan Facility due 2028 [Member]" } } }, "localname": "TermLoanFacilityDueTwentyTwentyEightMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TermLoanFacilityDueTwentyTwentySixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan facility due twenty twenty six.", "label": "Term Loan Facility Due Twenty Twenty Six [Member]", "terseLabel": "2026 Term Loans [Member]", "verboseLabel": "Term Loan Facility due 2026 [Member]" } } }, "localname": "TermLoanFacilityDueTwentyTwentySixMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TradeshowEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tradeshow equipment.", "label": "Tradeshow Equipment [Member]", "terseLabel": "Trade Show Equipment [Member]" } } }, "localname": "TradeshowEquipmentMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "hznp_TwentyEighteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Equity Incentive Plan.", "label": "Twenty Eighteen Equity Incentive Plan [Member]", "terseLabel": "2018 EIP [Member]", "verboseLabel": "2018 EIP [Member]" } } }, "localname": "TwentyEighteenEquityIncentivePlanMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwentyTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty equity incentive plan member.", "label": "Twenty Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 EIP [Member]", "verboseLabel": "2020 EIP [Member]" } } }, "localname": "TwentyTwentyEquityIncentivePlanMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwentyTwentyFourSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty twenty four senior notes.", "label": "Twenty Twenty Four Senior Notes [Member]", "terseLabel": "2024 Senior Notes [Member]" } } }, "localname": "TwentyTwentyFourSeniorNotesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwentyTwentySevenSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty twenty seven senior notes.", "label": "Twenty Twenty Seven Senior Notes [Member]", "terseLabel": "2027 Senior Notes [Member]" } } }, "localname": "TwentyTwentySevenSeniorNotesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwentyTwentyThreeSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty Twenty Three Senior Notes.", "label": "Twenty Twenty Three Senior Notes [Member]", "terseLabel": "2023 Senior Notes [Member]" } } }, "localname": "TwentyTwentyThreeSeniorNotesMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwoThousandFourteenEmployeeSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand fourteen employee share purchase plan.", "label": "Two Thousand Fourteen Employee Share Purchase Plan [Member]", "terseLabel": "2014 ESPP [Member]" } } }, "localname": "TwoThousandFourteenEmployeeSharePurchasePlanMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwoThousandFourteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand fourteen equity incentive plan.", "label": "Two Thousand Fourteen Equity Incentive Plan [Member]", "terseLabel": "2014 EIP [Member]" } } }, "localname": "TwoThousandFourteenEquityIncentivePlanMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwoThousandFourteenNonEmployeeEquityStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand fourteen nonemployee equity stock purchase plan.", "label": "Two Thousand Fourteen Non Employee Equity Stock Purchase Plan [Member]", "terseLabel": "2014 Non-Employee Equity Plan [Member]" } } }, "localname": "TwoThousandFourteenNonEmployeeEquityStockPurchasePlanMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwoThousandFourteenNonEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand fourteen nonemployee stock purchase plan.", "label": "Two Thousand Fourteen Non Employee Stock Purchase Plan [Member]", "terseLabel": "2014 Non-Employee Equity Plan [Member]", "verboseLabel": "2014 Non-Employee Plan [Member]" } } }, "localname": "TwoThousandFourteenNonEmployeeStockPurchasePlanMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwoThousandTwentyEmployeeSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty employee share purchase plan member", "label": "Two Thousand Twenty Employee Share Purchase Plan [Member]", "terseLabel": "2020 ESPP [Member]", "verboseLabel": "2020 ESPP [Member]" } } }, "localname": "TwoThousandTwentyEmployeeSharePurchasePlanMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_UPLIZNAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UPLIZNA member.", "label": "U P L I Z N A [Member]", "terseLabel": "UPLIZNA [Member]" } } }, "localname": "UPLIZNAMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_USFoodAndDrugAdministrationFDAApprovalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. food and drug administration (FDA) approval.", "label": "U S Food And Drug Administration F D A Approval [Member]", "terseLabel": "U.S. Food and Drug Administration (FDA) Approval [Member]" } } }, "localname": "USFoodAndDrugAdministrationFDAApprovalMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_USRetireeMedicalPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. retiree medical plan.", "label": "U S Retiree Medical Plan [Member]", "terseLabel": "U.S. Retiree Medical Plan [Member]" } } }, "localname": "USRetireeMedicalPlanMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineBenefitObligationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "domainItemType" }, "hznp_UnderwrittenPublicOfferingEquityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwritten public offering equity.", "label": "Underwritten Public Offering Equity [Member]", "terseLabel": "Underwritten Public Equity Offering [Member]" } } }, "localname": "UnderwrittenPublicOfferingEquityMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwritten public offering.", "label": "Underwritten Public Offering [Member]", "terseLabel": "Underwritten Public Offering", "verboseLabel": "2018 Offering [Member]" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthoritiesAndLapseOfApplicableStatuteOfLimitations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized tax benefits decreases resulting from settlements with taxing authorities and lapse of applicable statute of limitations.", "label": "Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities And Lapse Of Applicable Statute Of Limitations", "negatedLabel": "Tax positions related to prior years, Settlements and lapses" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthoritiesAndLapseOfApplicableStatuteOfLimitations", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesChangesInUncertainIncomeTaxPositionsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_UpFrontCashPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UpFront cash payment", "label": "Up Front Cash Payment", "terseLabel": "Upfront cash payment" } } }, "localname": "UpFrontCashPayment", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_UpfrontPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Upfront payment.", "label": "Upfront Payment [Member]", "terseLabel": "Upfront Payment [Member]" } } }, "localname": "UpfrontPaymentMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ValuationAllowancesAndReservesPaymentsRelatingToSalesInPriorYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments relating to sales in prior years.", "label": "Valuation Allowances And Reserves Payments Relating To Sales In Prior Year", "negatedLabel": "Payments relating to prior-year sales", "terseLabel": "Payments relating to prior-year sales" } } }, "localname": "ValuationAllowancesAndReservesPaymentsRelatingToSalesInPriorYear", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_VecturaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vectura.", "label": "Vectura [Member]", "terseLabel": "Vectura [Member]" } } }, "localname": "VecturaMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_VielaAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Viela acquisition member.", "label": "Viela Acquisition", "terseLabel": "Viela [Member]", "verboseLabel": "Viela Acquisition [Member]" } } }, "localname": "VielaAcquisitionMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_VielaBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Viela bio member.", "label": "Viela Bio [Member]", "terseLabel": "Viela Bio [Member]" } } }, "localname": "VielaBioMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_VimovoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VIMOVO.", "label": "Vimovo [Member]", "terseLabel": "VIMOVO [Member]" } } }, "localname": "VimovoMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail" ], "xbrltype": "domainItemType" }, "hznp_WashingtonDCOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Washington, D.C. office.", "label": "Washington D C Office [Member]", "terseLabel": "Washington, D.C. Office [Member]" } } }, "localname": "WashingtonDCOfficeMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_WriteOffOfUSDeferredTaxAssetRelatedToInterestExpenseDueToAntiHybridRules": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of U.S. deferred tax asset related to interest expense due to Anti-Hybrid Rules.", "label": "Write Off Of U S Deferred Tax Asset Related To Interest Expense Due To Anti Hybrid Rules", "terseLabel": "Write-off of U.S. deferred tax asset related to interest expense due to Anti-Hybrid Rules" } } }, "localname": "WriteOffOfUSDeferredTaxAssetRelatedToInterestExpenseDueToAntiHybridRules", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "hznp_XerisPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xeris Pharmaceuticals, Inc.", "label": "Xeris Pharmaceuticals, Inc [Member]" } } }, "localname": "XerisPharmaceuticalsIncMember", "nsuri": "http://www.horizontherapeutics.com/20221231", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r427", "r881", "r974", "r1097" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r471", "r472", "r473", "r474", "r583", "r775", "r811", "r843", "r844", "r878", "r888", "r899", "r971", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r471", "r472", "r473", "r474", "r583", "r775", "r811", "r843", "r844", "r878", "r888", "r899", "r971", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r427", "r881", "r974", "r1097" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProFormaMember": { "auth_ref": [ "r369", "r913", "r914" ], "lang": { "en-us": { "role": { "documentation": "Information reported based on historical fact adjusted for potential activity. Includes, but is not limited to, information expected to be reported in future period for effect on historical fact. Excludes forecast information.", "label": "Pro Forma [Member]", "terseLabel": "Pro forma [Member]" } } }, "localname": "ProFormaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfProFormaCombinedResultsDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r423", "r780", "r879", "r897", "r966", "r967", "r974", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r423", "r780", "r879", "r897", "r966", "r967", "r974", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r471", "r472", "r473", "r474", "r548", "r583", "r619", "r620", "r621", "r774", "r775", "r811", "r843", "r844", "r878", "r888", "r899", "r963", "r971", "r1088", "r1089", "r1090", "r1091", "r1092" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r471", "r472", "r473", "r474", "r548", "r583", "r619", "r620", "r621", "r774", "r775", "r811", "r843", "r844", "r878", "r888", "r899", "r963", "r971", "r1088", "r1089", "r1090", "r1091", "r1092" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r294", "r352", "r353", "r354", "r355", "r356", "r359", "r360", "r361", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r380", "r440", "r441", "r667", "r702", "r706", "r707", "r708", "r750", "r766", "r767", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823" ], "lang": { "en-us": { "role": { "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfProFormaCombinedResultsDetail" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r294", "r352", "r353", "r354", "r355", "r356", "r359", "r360", "r361", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r380", "r440", "r441", "r667", "r702", "r706", "r707", "r708", "r750", "r766", "r767", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823" ], "lang": { "en-us": { "role": { "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfProFormaCombinedResultsDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r588", "r940", "r1099" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]", "terseLabel": "Scenario Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r294", "r352", "r354", "r355", "r356", "r359", "r360", "r368", "r380", "r667", "r702", "r706", "r707", "r750", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r938", "r939", "r941", "r942", "r943", "r950", "r951", "r1075", "r1081", "r1082" ], "lang": { "en-us": { "role": { "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Previously Reported [Member]", "terseLabel": "As reported [Member]" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfProFormaCombinedResultsDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r369", "r588", "r913", "r940" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r351", "r855" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Schedule II - Valuation and Qualifying Accounts" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r424", "r425", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r845", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r880", "r898", "r974" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfTotalLongLivedAssetsByLocationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r424", "r425", "r827", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r845", "r846", "r880", "r898", "r974" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfTotalLongLivedAssetsByLocationDetail" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r369", "r588", "r913", "r914", "r940" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Scenario" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r947", "r1083" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2022", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "Valuation And Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebates", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesTables", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r345", "r346", "r347", "r349", "r350", "r855" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "Valuation And Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebates", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesTables", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebates" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r33", "r896" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r828" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedAdvertisingCurrentAndNoncurrent": { "auth_ref": [ "r17", "r20", "r264", "r280" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for advertising of the entity's goods and services.", "label": "Accrued Advertising", "terseLabel": "Advertising and marketing" } } }, "localname": "AccruedAdvertisingCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Consulting and professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r37", "r858" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "verboseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r125", "r304" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r53", "r54", "r55", "r310", "r805", "r819", "r823" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "verboseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r52", "r55", "r217", "r767", "r814", "r815", "r918", "r919", "r920", "r935", "r936", "r937" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquisitionRelatedCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information).", "label": "Acquisition-related Costs [Member]", "terseLabel": "Acquisition Related Costs [Member]" } } }, "localname": "AcquisitionRelatedCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r25" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r631", "r632", "r633", "r935", "r936", "r937", "r1074" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r355", "r356", "r357", "r358", "r369", "r431", "r432", "r436", "r437", "r438", "r439", "r440", "r441", "r631", "r632", "r633", "r664", "r665", "r666", "r667", "r683", "r684", "r685", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r742", "r743", "r747", "r748", "r749", "r750", "r762", "r763", "r764", "r765", "r766", "r767", "r782", "r783", "r784", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Ordinary shares withheld for payment of employees\u2019 withholding tax liability" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r177", "r178", "r591" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation", "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvancesOnInventoryPurchases": { "auth_ref": [ "r916" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.", "label": "Advances on Inventory Purchases", "terseLabel": "Advance payments for inventory" } } }, "localname": "AdvancesOnInventoryPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Expenses" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r637" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expenses" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r624" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "negatedLabel": "Share-based compensation", "verboseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForUncollectibleCustomersLiabilityForAcceptancesMember": { "auth_ref": [ "r928", "r929", "r930", "r932", "r933" ], "lang": { "en-us": { "role": { "documentation": "Allowance for portion expected to be uncollectible of receivable from customer for short-term negotiable time draft drawn on and accepted by financial institution (banker's acceptance).", "label": "SEC Schedule, 12-09, Allowance, Uncollectible Customer's Liability for Acceptances [Member]", "terseLabel": "Customer-related Accruals and Allowances [Member]" } } }, "localname": "AllowanceForUncollectibleCustomersLiabilityForAcceptancesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "domainItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r506", "r744", "r876", "r877", "r923" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and deferred financing costs", "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r79", "r113", "r118" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Intangible amortization expense", "terseLabel": "Amortization expense of developed technology" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [ "r884" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.", "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax", "totalLabel": "Total recognized in net periodic benefit cost and other comprehensive (income) loss" } } }, "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Reconciliation of basic and diluted earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Office space", "terseLabel": "Approximate Square Feet", "verboseLabel": "Approximate square feet of office space" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r1069" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r1069" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r79", "r122" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "negatedLabel": "Impairment of long-lived assets", "terseLabel": "Impairment of long-lived asset", "totalLabel": "Asset Impairment Charges, Total", "verboseLabel": "Impairment of long-lived asset" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r261", "r279", "r308", "r340", "r401", "r413", "r419", "r435", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r688", "r692", "r718", "r896", "r969", "r970", "r1085" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r299", "r313", "r340", "r435", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r688", "r692", "r718", "r896", "r969", "r970", "r1085" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets at fair value", "totalLabel": "Assets, Fair Value Disclosure, Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r594", "r595", "r596", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r618", "r619", "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedAndLongtermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2022RelativeTsrPsusDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r225", "r230" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Bank Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate [Member]" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r682", "r886", "r887" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r205", "r206", "r682", "r886", "r887" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format.", "label": "Business Acquisition, Date of Acquisition Agreement", "terseLabel": "Business acquisition agreement date" } } }, "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "auth_ref": [ "r198", "r199", "r200" ], "lang": { "en-us": { "role": { "documentation": "Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format.", "label": "Business Acquisition, Effective Date of Acquisition", "terseLabel": "Business Acquisition, Date of Acquisition Agreement" } } }, "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Equity value, shares" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsParentheticalDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of equity interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Share price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsParentheticalDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r680", "r681" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net income, Pro forma" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r197" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedLabel": "Acquisition/divestiture-related costs", "terseLabel": "Acquisition-related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r211", "r212", "r213" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total consideration for acquisition", "totalLabel": "Total consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r211", "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Equity value (54,988,820 shares at $53.00 per share)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r215" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Milestone Payment" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r208" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "terseLabel": "Business acquisition, asset", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 11.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities", "terseLabel": "Marketable securities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "negatedLabel": "Accrued expenses and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred tax liabilities, net", "terseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 12.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "In-process research and development" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r207", "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 13.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Developed technology" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r207", "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 10.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r207", "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "(Liabilities assumed) and assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedLabel": "Other long-term liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r207", "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r208" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Fair value of consideration paid" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "terseLabel": "Business acquisition, costs" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.", "label": "Business Combination, Separately Recognized Transactions [Axis]", "terseLabel": "Business Combination, Separately Recognized Transactions" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.", "label": "Business Combination, Separately Recognized Transactions [Domain]", "terseLabel": "Business Combination, Separately Recognized Transactions" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r84", "r85", "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property, plant and equipment included in accounts payable and accrued expenses and other current liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r825", "r826", "r896", "r915" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash on hand" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Cash acquired from acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r81", "r302", "r856" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r82", "r259" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r76", "r81", "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the year", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the year", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r76", "r253" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r42", "r267", "r285" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r130", "r468", "r469", "r829", "r968" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r134", "r830" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r935", "r936", "r1074" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Ordinary Shares [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Ordinary shares, nominal value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Ordinary shares, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Ordinary shares, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r141" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Ordinary shares, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r896" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at December 31, 2022 and December 31, 2021; 227,625,913 and 227,760,936 shares issued at December 31, 2022 and December 31, 2021, respectively; and 227,241,547 and 227,376,570 shares outstanding at December 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r57", "r320", "r322", "r329", "r801", "r807" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r94", "r95", "r250", "r251", "r427", "r828" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r94", "r95", "r250", "r251", "r427", "r824", "r828" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r94", "r95", "r250", "r251", "r427", "r828", "r1098" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r274", "r386" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r94", "r95", "r250", "r251", "r427" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Consolidated receivable/sales percentage to major customers", "terseLabel": "Percentage of concentration risk", "verboseLabel": "Total Net Sales, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r94", "r95", "r250", "r251", "r427", "r828" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r216", "r864" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Process [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerRefundLiability": { "auth_ref": [ "r975" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.", "label": "Contract with Customer, Refund Liability", "periodEndLabel": "Refund liability", "periodStartLabel": "Refund liability", "totalLabel": "Contract with Customer, Refund Liability, Total" } } }, "localname": "ContractWithCustomerRefundLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfChangesToRefundLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "auth_ref": [ "r975" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.", "label": "Contract with Customer, Refund Liability, Current", "terseLabel": "Less: current portion" } } }, "localname": "ContractWithCustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfChangesToRefundLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityNoncurrent": { "auth_ref": [ "r975" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as noncurrent.", "label": "Contract with Customer, Refund Liability, Noncurrent", "terseLabel": "Refund liability, net of current portion", "totalLabel": "Contract with Customer, Refund Liability, Noncurrent, Total" } } }, "localname": "ContractWithCustomerRefundLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfChangesToRefundLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r62", "r780" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold", "totalLabel": "Cost of Goods and Services Sold, Total" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Goods Sold [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r976" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Goods Sold" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r193", "r661", "r671", "r926" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "terseLabel": "Total current expense (benefit) provision", "totalLabel": "Current Income Tax Expense (Benefit), Total" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current expense (benefit) provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r92", "r427" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRefundLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.", "label": "Customer Refund Liability, Current", "terseLabel": "Refund liability" } } }, "localname": "CustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r84", "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Principal amount of 2.5% Exchangeable Senior Notes due 2022 converted into ordinary shares" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r140", "r338", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r500", "r507", "r508", "r510" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt Agreements" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r262", "r265", "r276", "r344", "r484", "r485", "r486", "r487", "r488", "r490", "r496", "r497", "r498", "r499", "r501", "r502", "r503", "r504", "r505", "r506", "r745", "r873", "r874", "r875", "r876", "r877", "r924" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r18", "r265", "r276", "r511" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "negatedTotalLabel": "Total", "terseLabel": "Outstanding principal amount", "totalLabel": "Total", "verboseLabel": "Total face value" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r137", "r486" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Exchange price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r498", "r717", "r874", "r875" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt instrument, fair value", "totalLabel": "Debt Instrument, Fair Value Disclosure, Total" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r40", "r271" ], "lang": { "en-us": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Debt instrument, frequency of periodic payment" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r39", "r255", "r513", "r745" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r39", "r485" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r314", "r873", "r1076" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date of debt instrument" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r40", "r344", "r484", "r485", "r486", "r487", "r488", "r490", "r496", "r497", "r498", "r499", "r501", "r502", "r503", "r504", "r505", "r506", "r745", "r873", "r874", "r875", "r876", "r877", "r924" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionDescription": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Description of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Description", "terseLabel": "Debt instrument redemption description" } } }, "localname": "DebtInstrumentRedemptionDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price as percentage of aggregate principal amount" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of debt redeemed.", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "terseLabel": "Redemption amount as percentage of aggregate principal amount" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r40", "r142", "r143", "r144", "r145", "r254", "r255", "r257", "r273", "r344", "r484", "r485", "r486", "r487", "r488", "r490", "r496", "r497", "r498", "r499", "r501", "r502", "r503", "r504", "r505", "r506", "r509", "r745", "r873", "r874", "r875", "r876", "r877", "r924" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r254", "r257", "r972" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Debt discount", "totalLabel": "Debt Instrument, Unamortized Discount, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": { "auth_ref": [ "r150", "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Compensation Expense", "verboseLabel": "Non-qualified deferred compensation plan expenses recognized" } } }, "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation plan liabilities", "totalLabel": "Deferred Compensation Liability, Classified, Noncurrent, Total" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r256", "r972" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Deferred financing fees", "totalLabel": "Debt Issuance Costs, Net, Total" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r643", "r644" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r79", "r193", "r662", "r670", "r671", "r926" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred (benefit) provision", "totalLabel": "Deferred Income Tax Expense (Benefit), Total" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r21", "r22", "r263", "r275", "r655" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r643", "r644" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Taxes and Other Assets [Abstract]", "terseLabel": "Deferred benefit provision" } } }, "localname": "DeferredIncomeTaxesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r656" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r1066" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "negatedTotalLabel": "Net deferred income tax asset", "totalLabel": "Deferred Tax Assets, Net, Total" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r1066" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r190", "r1067" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "U.S. federal and state credits" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r190", "r1067" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "auth_ref": [ "r190", "r1067" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation", "terseLabel": "Accrued compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r657" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "negatedPeriodEndLabel": "Ending Balance", "negatedPeriodStartLabel": "Beginning Balance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfValuationAllowanceDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": { "auth_ref": [ "r190", "r1067" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.", "label": "Deferred Tax Liabilities, Financing Arrangements", "terseLabel": "Debt discount" } } }, "localname": "DeferredTaxLiabilitiesFinancingArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r190", "r1067" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r190", "r1067" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfDomesticSubsidiaries": { "auth_ref": [ "r678" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of domestic subsidiaries.", "label": "Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Domestic Subsidiaries", "terseLabel": "Estimates income tax unremitted earnings" } } }, "localname": "DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfDomesticSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "auth_ref": [ "r50", "r55", "r1018" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "totalLabel": "Accumulated other comprehensive loss before income taxes" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax [Abstract]" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "auth_ref": [ "r55", "r562" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "negatedLabel": "Actuarial (gain) loss" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r55", "r562" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail": { "order": 0.0, "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "terseLabel": "Prior service cost" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r545" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedLabel": "Actuarial (gain) loss", "terseLabel": "Actuarial (gain) loss" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r541", "r560", "r575", "r884", "r885" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of prior service cost" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r260", "r278", "r539", "r540", "r547", "r884" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "negatedTotalLabel": "Amounts recognized on the consolidated balance sheet", "terseLabel": "Deferred compensation plan assets funds held" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineBenefitObligationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r542" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Benefit obligation at end of year", "periodStartLabel": "Benefit obligation at beginning of year" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r546", "r578" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedLabel": "Benefits paid net of participant contributions" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineBenefitObligationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedAmountsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Expected Amounts [Abstract]" } } }, "localname": "DefinedBenefitPlanExpectedAmountsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "2028 to 2031" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2027" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2026" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r539", "r547", "r884" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "terseLabel": "Unfunded status for the retiree medical plan", "totalLabel": "Defined Benefit Plan, Funded (Unfunded) Status of Plan, Total" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "terseLabel": "Health care cost trend rate assumed for next year" } } }, "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r541", "r544", "r559", "r574", "r884", "r885" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r557", "r572", "r884", "r885" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail": { "order": 0.0, "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "auth_ref": [ "r557", "r572" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DefinedBenefitPlanOtherCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of defined benefit plan cost (credit), classified as other.", "label": "Defined Benefit Plan, Other Cost (Credit)", "terseLabel": "Defined benefit plan expenses" } } }, "localname": "DefinedBenefitPlanOtherCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r543", "r558", "r573", "r884", "r885" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail": { "order": 0.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "terseLabel": "Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)", "verboseLabel": "Ultimate trend rate" } } }, "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Year ultimate health care cost trend rate is expected to be reached, in YYYY format.", "label": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate", "terseLabel": "Year that the rate reaches the ultimate trend rate" } } }, "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail" ], "xbrltype": "gYearListItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Percent of matching contribution by company" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage", "terseLabel": "Percent of employee's eligible pay" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum percent of employee's elective contribution to plan" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r79", "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "negatedLabel": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r79", "r396" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r47", "r48", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "terseLabel": "Derivative asset, subject to master netting arrangement, liability offset" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentDetailAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instrument Detail [Abstract]" } } }, "localname": "DerivativeInstrumentDetailAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r226", "r228", "r236", "r238", "r863" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r244", "r696" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivities1" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r223", "r226", "r236" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r223", "r226", "r236", "r238", "r242", "r243", "r694" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Assets, at Fair Value", "totalLabel": "Fair value-Derivatives in asset position, Total derivatives" } } }, "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "terseLabel": "Fair value-Derivatives in liability position, Total derivatives" } } }, "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "auth_ref": [ "r47", "r48", "r227", "r862" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset", "terseLabel": "Derivative liability, subject to master netting arrangement, asset offset" } } }, "localname": "DerivativeLiabilityFairValueGrossAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r1071", "r1072" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r219", "r220", "r221", "r223", "r224", "r231", "r236", "r240", "r241", "r243", "r696" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts.", "label": "Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities" } } }, "localname": "DerivativesMethodsOfAccountingHedgingDerivatives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DilutiveSecurities": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.", "label": "Dilutive Securities, Effect on Basic Earnings Per Share", "terseLabel": "Numerator - net income", "totalLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Total" } } }, "localname": "DilutiveSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "terseLabel": "Effect of assumed conversion of 2.50% Exchangeable Senior Notes due 2022, net of tax" } } }, "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r593", "r625", "r626", "r629", "r635", "r889" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based and Long-Term Incentive Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal group that is not classified as discontinued operations.", "label": "Disposal Group, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Not Discontinued Operations [Member]" } } }, "localname": "DisposalGroupNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r886", "r887" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "U.S. Federal Tax [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r330", "r359", "r360", "r362", "r363", "r364", "r370", "r372", "r374", "r375", "r376", "r380", "r707", "r708", "r802", "r808", "r870" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income per ordinary share\u2014basic", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Basic net income per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic net income per share calculation:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r330", "r359", "r360", "r362", "r363", "r364", "r372", "r374", "r375", "r376", "r380", "r707", "r708", "r802", "r808", "r870" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income per ordinary share\u2014diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Diluted net income per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted net income per share calculation:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r89", "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r377", "r378", "r379", "r381" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShare1" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r731" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate", "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r1064", "r1068" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "verboseLabel": "Effective income tax statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll-related expenses", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r628" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Pre-tax unrecognized compensation expense for all unvested share-based awards", "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r630" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "terseLabel": "Share based compensation, tax credits" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Share Purchase Plans Shares [Member]", "verboseLabel": "Employee Stock Purchase Plans [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r141", "r293", "r324", "r325", "r326", "r352", "r353", "r354", "r356", "r365", "r368", "r383", "r439", "r526", "r631", "r632", "r633", "r666", "r667", "r706", "r732", "r733", "r734", "r735", "r736", "r738", "r767", "r814", "r815", "r816" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r75", "r109", "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Net unrealized gains on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r809", "r948" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Net unrealized (losses) gains on equity securities", "totalLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss), Total" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r108", "r277", "r900", "r901", "r902" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r710", "r711", "r715" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r245", "r247" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r498", "r550", "r551", "r552", "r553", "r554", "r555", "r711", "r771", "r772", "r773", "r874", "r875", "r882", "r883", "r884" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r710", "r711", "r712", "r713", "r716" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r498", "r550", "r555", "r711", "r771", "r882", "r883", "r884" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r498", "r550", "r555", "r711", "r772", "r874", "r875", "r882", "r883", "r884" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r498", "r550", "r551", "r552", "r553", "r554", "r555", "r711", "r773", "r874", "r875", "r882", "r883", "r884" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r498", "r550", "r551", "r552", "r553", "r554", "r555", "r771", "r772", "r773", "r874", "r875", "r882", "r883", "r884" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r714", "r716" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value Measurements, Recurring Basis [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r225", "r231", "r242" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Useful life of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r306", "r461" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r119" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r119" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r119" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r119" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r119" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r458", "r460", "r461", "r462", "r781", "r785" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r117", "r785" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail": { "order": 0.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost Basis", "totalLabel": "Finite-Lived Intangible Assets, Gross, Total" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r114", "r116" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-Lived Intangible Assets [Member]", "terseLabel": "Definite-Lived Intangible Assets [Member]" } } }, "localname": "FiniteLivedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r117", "r781" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "terseLabel": "Developed technology and other intangible assets, net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r781" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Finite-lived intangible assets, remaining amortization period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Capitalized payments of intangible assets", "verboseLabel": "Intangible assets acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "auth_ref": [ "r229" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.", "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value", "terseLabel": "Fair value-Derivatives in asset position, Not designated as hedges" } } }, "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.", "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value", "terseLabel": "Fair value-Derivatives in liability position, Not designated as hedges" } } }, "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyExchangeRateTranslation1": { "auth_ref": [ "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.", "label": "Foreign Currency Exchange Rate, Translation", "terseLabel": "Currency exchange rate" } } }, "localname": "ForeignCurrencyExchangeRateTranslation1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign Exchange Gain (Loss) [Member]" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r727", "r728", "r729", "r730" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign exchange loss", "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Currency Contracts [Member]" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnComponentsExcludedFromAssessmentOfForeignCurrencyCashFlowHedgeEffectiveness": { "auth_ref": [ "r235" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net gain (loss) relating to components of the gain (loss) on foreign currency cash flow hedging instruments excluded from the assessment of hedge effectiveness. Recognized in earnings.", "label": "Gain (Loss) on Components Excluded from Assessment of Foreign Currency Cash Flow Hedge Effectiveness", "terseLabel": "Amount excluded from assessment of effectiveness for cash flow hedges" } } }, "localname": "GainLossOnComponentsExcludedFromAssessmentOfForeignCurrencyCashFlowHedgeEffectiveness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r226" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain (loss) on derivative instruments, net, pretax", "totalLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax, Total" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r923" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Net income", "negatedLabel": "Gain on sale of assets", "netLabel": "Loss on sale of assets", "terseLabel": "Net loss", "totalLabel": "Loss on sale of assets", "verboseLabel": "(Gain) loss on sale of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfProFormaCombinedResultsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainOnDerivativeInstrumentsPretax": { "auth_ref": [ "r226" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain on Derivative Instruments, Pretax", "terseLabel": "Interest rate swap contracts designated as cash flow hedges" } } }, "localname": "GainOnDerivativeInstrumentsPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r79", "r138", "r139" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on debt extinguishment", "terseLabel": "Loss on debt extinguishment", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralDiscussionOfDerivativeInstrumentsAndHedgingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General Discussion of Derivative Instruments and Hedging Activities [Abstract]" } } }, "localname": "GeneralDiscussionOfDerivativeInstrumentsAndHedgingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r93", "r828" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r305", "r445", "r799", "r872", "r896", "r952", "r959" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill ending balance", "periodStartLabel": "Goodwill beginning balance", "terseLabel": "Goodwill", "totalLabel": "Goodwill, Total" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r447", "r454", "r872" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Accumulated goodwill impairment losses" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r79", "r446", "r451", "r457", "r872" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedLabel": "Goodwill impairment during the year", "terseLabel": "Goodwill impairment", "verboseLabel": "Impairment of goodwill" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r196", "r958" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Net reduction in goodwill" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r61", "r340", "r401", "r412", "r418", "r421", "r435", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r718", "r871", "r969" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r223", "r694" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLeasehold": { "auth_ref": [ "r79", "r122" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.", "label": "Impairment of Leasehold", "terseLabel": "Impairment charge" } } }, "localname": "ImpairmentOfLeasehold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r341", "r672" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r59", "r258", "r268", "r287", "r401", "r412", "r418", "r421", "r803", "r871" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (loss) before (benefit) expense for income taxes", "totalLabel": "Income before expense (benefit) for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r341", "r672" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Income (loss) before (benefit) expense for income taxes, Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r886", "r887" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfProFormaCombinedResultsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r9", "r10", "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfProFormaCombinedResultsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsScheduleOfTotalConsiderationForAcquisitionsParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r463", "r465" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r184", "r185", "r186", "r192" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesCompanysIncomeBeforeExpenseBenefitForIncomeTaxesByJurisdictionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r342", "r647", "r653", "r660", "r668", "r673", "r675", "r676", "r679" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r343", "r367", "r368", "r399", "r645", "r669", "r674", "r810" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "(Benefit) expense for income taxes", "totalLabel": "Expense (benefit) for income taxes", "verboseLabel": "Expense (benefit) for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxHolidayLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Holiday [Line Items]", "terseLabel": "Income Tax Holiday [Line Items]" } } }, "localname": "IncomeTaxHolidayLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxHolidayTable": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Income tax-exemptions and reductions which may be granted by a taxing authority for a specified period. Such \"tax holidays\" are typically granted to induce business investment in the tax jurisdiction.", "label": "Income Tax Holiday [Table]", "terseLabel": "Income Tax Holiday [Table]" } } }, "localname": "IncomeTaxHolidayTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureIncomeTaxesComponentsOfExpenseBenefitForIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r323", "r641", "r642", "r653", "r654", "r659", "r663" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Provision for Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r1064" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 12.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowances", "verboseLabel": "Tax expense on increases in net valuation allowances" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r640", "r646" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "negatedLabel": "Tax benefit of recognized due to reduction in state tax rate" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r1064" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign tax rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r646" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Irish income tax at statutory rate (12.5%)" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r1064" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 15.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "terseLabel": "Disqualified compensation expense", "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount, Total", "verboseLabel": "Tax expense on non-deductible officer's compensation expenses" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r1064" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount", "terseLabel": "Goodwill impairment" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r1064" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 13.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "terseLabel": "Other non-deductible expenses" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r1064" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount", "terseLabel": "Non-deductible in-process research and development costs", "verboseLabel": "Tax effect on non-deductible IPR&D expenses" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r1064" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "terseLabel": "Share-based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r1064" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 16.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other, net" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r1064" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount", "verboseLabel": "Tax benefits partially set off by tax expense" } } }, "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r1064" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "U.S. state income taxes" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsOther": { "auth_ref": [ "r1064" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount", "negatedLabel": "U.S. federal and state tax credits", "terseLabel": "U.S. federal and state tax credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenIrishStatutoryIncomeTaxRateAndUSFederalStatutoryIncomeTaxRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes, net of refunds received", "totalLabel": "Income Taxes Paid, Net, Total" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r78" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r78" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r78" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r78" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "totalLabel": "Increase (Decrease) in Inventories, Total" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r78" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other non-current assets and liabilities", "totalLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r78" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r120" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "periodEndLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance", "periodStartLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance", "terseLabel": "In-process research and development", "totalLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Total" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r116", "r777", "r778", "r779", "r781", "r865" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r112", "r115" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Net Book Value" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense, Net [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r332", "r335", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 9.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeAssetAtFairValue": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all interest rate derivative assets designated as cash flow hedging instruments.", "label": "Interest Rate Cash Flow Hedge Asset at Fair Value", "terseLabel": "Fair value-Derivatives in asset position, Designated as cash flow hedges" } } }, "localname": "InterestRateCashFlowHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r894" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap Contracts [Member]" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountsOfGainsFromDerivativeInstrumentsRecognizedInOtherComprehensiveInco", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r110", "r859" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoriesDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods", "verboseLabel": "Inventory, finished goods, gross" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r312", "r857", "r896" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoriesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoriesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r301", "r311", "r382", "r442", "r443", "r444", "r776", "r866" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r110", "r861" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoriesDetail": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials", "verboseLabel": "Inventory, raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r110", "r860" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoriesDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process", "verboseLabel": "Inventory, work in Process, gross" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyCommittedCapital": { "auth_ref": [ "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of funds committed to investment company from investors.", "label": "Investment Company, Committed Capital", "terseLabel": "Amount committed in investment" } } }, "localname": "InvestmentCompanyCommittedCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r434", "r1095" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r710" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments in equity securities held in fair value", "totalLabel": "Investments, Fair Value Disclosure, Total" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandAndLandImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate held and assets that are an addition or improvement to real estate held.", "label": "Land and Land Improvements [Member]", "terseLabel": "Land Improvements [Member]", "verboseLabel": "Land and Land Improvements [Member]" } } }, "localname": "LandAndLandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Lease Expiry Date", "verboseLabel": "Lease expiry date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Proceedings" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r756" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r754" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r755" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Option to extend", "verboseLabel": "Lessee, operating lease, existence of option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": { "auth_ref": [ "r755" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]", "terseLabel": "Lessee, operating lease, existence of option to terminate" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r1079" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Lease Liabilities Recorded on the Balance Sheet" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r760" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Lease liabilities,Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r760" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Lease liabilities, Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r760" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Lease liabilities, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r760" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Lease liabilities, 2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r760" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Lease liabilities, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r760" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Lease liabilities, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r760" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Lease liabilities, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r760" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Lease liabilities, Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r761" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease Obligations" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r266", "r283", "r896", "r925", "r949", "r1077" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r38", "r300", "r340", "r435", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r689", "r692", "r693", "r718", "r896", "r969", "r1085", "r1086" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "negatedLabel": "Total liabilities at fair value", "totalLabel": "Liabilities, Fair Value Disclosure, Total" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r13", "r14", "r15", "r18", "r19", "r340", "r435", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r689", "r692", "r693", "r718", "r969", "r1085", "r1086" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "LONG-TERM LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.", "label": "Liability for Uncertainty in Income Taxes, Noncurrent", "terseLabel": "Uncertain tax positions, interest and penalties included in long-term liabilities" } } }, "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityDescription": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.", "label": "Line of Credit Facility, Description", "terseLabel": "Credit agreement, description" } } }, "localname": "LineOfCreditFacilityDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDescription": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate.", "label": "Line of Credit Facility, Interest Rate Description", "terseLabel": "Interest rate description" } } }, "localname": "LineOfCreditFacilityInterestRateDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Aggregate principal amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Summary of Total Long-Lived Assets by Location" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r18", "r265", "r281", "r497", "r512", "r874", "r875" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail2": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Less: current maturities", "totalLabel": "Long-Term Debt, Current Maturities, Total" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r135", "r344", "r973" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "negatedLabel": "Thereafter", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r135", "r344", "r502" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail": { "order": 0.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "negatedLabel": "2023", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r135", "r344", "r502" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "negatedLabel": "2027", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r135", "r344", "r502" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "negatedLabel": "2026", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r135", "r344", "r502" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "negatedLabel": "2025", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r135", "r344", "r502" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "negatedLabel": "2024", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsScheduledMaturitiesOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r309" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail2": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of current maturities", "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.", "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate", "terseLabel": "Debt instrument, variable interest rate" } } }, "localname": "LongTermDebtPercentageBearingVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Minimum binding purchase commitment" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r40", "r136" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r132", "r133", "r470", "r471", "r472", "r964", "r965" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r999" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r334" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r334" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r76", "r77", "r80" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r60", "r80", "r269", "r286", "r298", "r318", "r321", "r326", "r340", "r355", "r359", "r360", "r362", "r363", "r367", "r368", "r373", "r401", "r412", "r418", "r421", "r435", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r708", "r718", "r871", "r969" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Numerator - net income", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Rest of World [Member]", "verboseLabel": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL NON-CASH FLOW INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r84", "r85", "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Milestone payments for TEPEZZA intangible asset included in accrued expenses and other current liabilities" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r425" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Total long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfTotalLongLivedAssetsByLocationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfPretaxAmountAndLocationsOfDerivativeInstrumentNetGainsLossesRecognizedInTheCo" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonrecurringAdjustmentAxis": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Axis]", "terseLabel": "Nonrecurring Adjustment" } } }, "localname": "NonrecurringAdjustmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NonrecurringAdjustmentDomain": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Domain]", "terseLabel": "Nonrecurring Adjustment" } } }, "localname": "NonrecurringAdjustmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r946" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r401", "r412", "r418", "r421", "r871" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating income", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r1078" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r752" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liabilities", "totalLabel": "Operating Lease, Liability, Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsScheduleOfLeaseLiabilitiesRecordedOnBalanceSheetDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r752" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r753" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r752" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liability, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r753" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r751" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r753" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r759", "r895" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r758", "r895" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.", "label": "Operating Loss Carryforwards, Limitations on Use", "terseLabel": "Operating loss carryforwards limitations on use" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r11", "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation and Business Overview" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverview" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r225", "r242" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets [Member]" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r307" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "verboseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.", "label": "Other Capitalized Property Plant and Equipment [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": { "auth_ref": [ "r51", "r53", "r561" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax", "terseLabel": "Prior service cost" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r53", "r56", "r317", "r561" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "negatedLabel": "Amortization of prior service cost" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r315", "r316" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Interest rate swap contracts designated as cash flow hedges", "totalLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Total" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r49" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "verboseLabel": "Currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r58", "r141", "r319", "r322", "r328", "r732", "r737", "r738", "r800", "r806", "r918", "r919" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "auth_ref": [ "r50", "r53", "r884", "r1017" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail": { "order": 1.0, "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "totalLabel": "Total recognized in other comprehensive (income) loss" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r50", "r53" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Pension and other post-employment benefit plan remeasurements", "totalLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax, Total" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r225", "r242" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeMember": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other revenue.", "label": "Other Income [Member]", "terseLabel": "Other Income (Expense), Net [Member]" } } }, "localname": "OtherIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangibles [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Long-Term Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Long-term Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER EXPENSE, NET:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r73" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of ordinary shares", "terseLabel": "Repurchase of ordinary shares" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r331" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Payment of employee withholding taxes relating to share-based awards", "terseLabel": "Payments for employee withholding taxes related to share-based payment" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r68", "r686" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Equity value (54,988,820 shares at $53.00 per share)", "verboseLabel": "Upfront cash payments" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r68" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Payments for acquisitions, net of cash acquired", "terseLabel": "Payments for acquisitions, net of cash acquired", "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payments to Acquire in Process Research and Development", "terseLabel": "Payment for acquisition of IPR&D asset" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "terseLabel": "Net cash payments for investment", "totalLabel": "Payments to Acquire Investments, Total" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "auth_ref": [ "r922" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.", "label": "Payments to Acquire Long-Term Investments", "negatedLabel": "Payments for long-term investments", "terseLabel": "Payments for long-term investments" } } }, "localname": "PaymentsToAcquireLongtermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": { "auth_ref": [ "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Payments to Acquire Other Property, Plant, and Equipment", "terseLabel": "Additional transaction cost" } } }, "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r69" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment", "terseLabel": "Upfront cash payments", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r548", "r549", "r555", "r565", "r567", "r568", "r569", "r570", "r571", "r576", "r577", "r579", "r589", "r884" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Stock Units [Member]", "verboseLabel": "Performance Stock Unit Awards [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedAndLongtermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2022RelativeTsrPsusDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitPlansPolicy": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.", "label": "Postemployment Benefit Plans, Policy [Policy Text Block]", "terseLabel": "Post-employment Benefits" } } }, "localname": "PostemploymentBenefitPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r917" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesSummeryOfAmountsAndLocationsOfDerivativeInstrumentsOnCondensedConsolidatedBalanceSheetDe" ], "xbrltype": "domainItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r71" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from the issuance of ordinary shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r72" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-Term Debt", "terseLabel": "Net proceeds from the issuance of senior notes" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r71", "r176" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from the issuance of ordinary shares in conjunction with Employee Share Purchase Plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r72" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-Term Lines of Credit", "terseLabel": "Net proceeds from term loans" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Proceeds from Sale of Intangible Assets", "terseLabel": "Rights sold for an upfront payment" } } }, "localname": "ProceedsFromSaleOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfLongtermInvestments": { "auth_ref": [ "r921" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.", "label": "Proceeds from Sale of Long-Term Investments", "terseLabel": "Receipts from long-term investments" } } }, "localname": "ProceedsFromSaleOfLongtermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r67" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from sale of assets", "totalLabel": "Proceeds from Sale of Productive Assets, Total" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r71", "r176" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the issuance of ordinary shares in connection with stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r298", "r318", "r321", "r333", "r340", "r355", "r367", "r368", "r401", "r412", "r418", "r421", "r435", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r687", "r690", "r691", "r708", "r718", "r803", "r871", "r892", "r893", "r920", "r969" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Additions", "terseLabel": "Purchase of building for consideration and transaction costs" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r129", "r831", "r832", "r833" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r124", "r303" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Total consideration", "totalLabel": "Property, Plant and Equipment, Gross, Total", "verboseLabel": "Total consideration" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r126", "r284", "r804", "r896" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r126", "r831", "r832" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfFairValuesOfAssetsAcquiredDetails", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Depreciation and amortization" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r101", "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Summary of Reconciliations of Segment Operating Income" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r566", "r768", "r769" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r566", "r768", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r1084" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r74" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-Term Lines of Credit", "negatedLabel": "Repayment of term loans" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments of Secured Debt", "terseLabel": "Line of credit facility borrowing capacity" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSeniorDebt": { "auth_ref": [ "r74" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.", "label": "Repayments of Senior Debt", "negatedLabel": "Repayment of senior notes", "totalLabel": "Repayments of Senior Debt, Total" } } }, "localname": "RepaymentsOfSeniorDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitAxis": { "auth_ref": [ "r456", "r457", "r872" ], "lang": { "en-us": { "role": { "documentation": "Information by reporting unit.", "label": "Reporting Unit [Axis]", "terseLabel": "Reporting Unit" } } }, "localname": "ReportingUnitAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReportingUnitDomain": { "auth_ref": [ "r456", "r457", "r872" ], "lang": { "en-us": { "role": { "documentation": "Level of reporting at which goodwill is tested for impairment.", "label": "Reporting Unit [Domain]", "terseLabel": "Reporting Unit" } } }, "localname": "ReportingUnitDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "terseLabel": "Percentage of fair value of reporting unit in excess of carrying amount." } } }, "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r179", "r289", "r1093" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]", "verboseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "R&D Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Acquired in-process research and development expense", "verboseLabel": "Acquired IPR&D and milestones" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r81", "r87", "r302" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r146", "r282", "r818", "r823", "r896" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r293", "r352", "r353", "r354", "r356", "r365", "r368", "r439", "r631", "r632", "r633", "r666", "r667", "r706", "r814", "r816" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "(Accumulated Deficit) Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r888", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037" ], "lang": { "en-us": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]", "terseLabel": "Retirement Plan Name" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineBenefitObligationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r888", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037" ], "lang": { "en-us": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]", "terseLabel": "Retirement Plan Name" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInConsolidatedBalanceSheetsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineBenefitObligationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfAmountsRecognizedInAccumulatedOtherComprehensiveLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameOtherMember": { "auth_ref": [ "r1025" ], "lang": { "en-us": { "role": { "documentation": "Retirement plan not separately disclosed by name classified as other.", "label": "Retirement Plan Name, Other [Member]", "terseLabel": "Other Employee Benefit Plans [Member]" } } }, "localname": "RetirementPlanNameOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r392", "r393", "r411", "r416", "r417", "r423", "r424", "r427", "r535", "r536", "r780" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Total net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfProFormaCombinedResultsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r427", "r945" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Sales Revenue [Member]" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r537", "r867" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Contractual Allowances" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Summary of Net Sales Attributed to Geographic Sources" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r867", "r868" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r327", "r340", "r392", "r393", "r411", "r416", "r417", "r423", "r424", "r427", "r435", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r718", "r803", "r969" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Revenues, Total" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "2026 Term Loans [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r757", "r895" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Lease liabilities arising from obtaining right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyGuaranteesCommitmentsAmount": { "auth_ref": [ "r786" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount the entity has committed to make for future royalty guarantees.", "label": "Royalty Guarantees, Commitments, Amount", "terseLabel": "Minimum annual royalty obligations" } } }, "localname": "RoyaltyGuaranteesCommitmentsAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesReturnsAndAllowancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.", "label": "Sales Returns and Allowances [Member]", "terseLabel": "Allowance for prompt pay discounts [Member]" } } }, "localname": "SalesReturnsAndAllowancesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent.", "label": "Scenario, Adjustment [Member]", "terseLabel": "Pro forma adjustments [Member]" } } }, "localname": "ScenarioAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsSummaryOfProFormaCombinedResultsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The scenario under which facts represent plans as distinct from actual.", "label": "Scenario, Plan [Member]", "terseLabel": "Scenario, Plan [Member]" } } }, "localname": "ScenarioPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "terseLabel": "Summary of Amounts Recognized in Consolidated Balance Sheets" } } }, "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.", "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summary of Net Period Benefit Cost Recognized and Amounts Recognized in Other Comprehensive (Income) Loss" } } }, "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Outstanding Securities Excluded from Computation of Diluted Income (Loss) Per Ordinary Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Summary of Weighted-Average Assumptions and Health Care Cost Trend Rates Used to Determine Benefit Obligation" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Total Consideration for the Acquisitions" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r205", "r206", "r682" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summery of Pre-tax Amounts of Gains From Derivative Instruments Recognized in Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Components of Expense (Benefit) for Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock": { "auth_ref": [ "r290", "r1080" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of the investment in leveraged leases.", "label": "Schedule of Components of Leveraged Lease Investments [Table Text Block]", "terseLabel": "Schedule of Office Space Lease Agreements in Place for Real Properties" } } }, "localname": "ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r40", "r142", "r143", "r144", "r145", "r254", "r255", "r257", "r273", "r874", "r876", "r927" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Outstanding Debt Balances" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Significant Components of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.", "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summary of Amounts Recognized in Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r155", "r156", "r157", "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfNetPeriodBenefitCostRecognizedAndAmountsRecognizedInOtherComprehensiveIncomeLossDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineBenefitObligationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansSummaryOfWeightedaverageAssumptionsAndHealthCareCostTrendRatesUsedToDetermineNetPeriodicBenefitCostsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfChangesInBenefitObligationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansSummaryOfTotalBenefitPaymentsWhichReflectExpectedFutureServiceExpectedToBePaidToPlanParticipantsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": { "auth_ref": [ "r155", "r156", "r157", "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.", "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "terseLabel": "Summary of Changes in Benefit Obligation" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r9", "r10", "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Gain (Loss) on Sale of Assets" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r944" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and Diluted Net Income per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation Between Irish Statutory Rate and U.S Federal Statutory Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Share-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Summary of Net Sales by Medicine" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Summary of Total Benefit Payments, Which Reflect Expected Future Service, Expected to Be Paid to Plan Participants" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r710", "r711" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Assets and Liabilities at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Summery of Amounts and Locations of Derivative Instruments on Condensed Consolidated Balance Sheet" } } }, "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r114", "r116", "r781" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r114", "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Amortizable Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r872" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule Of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r872", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill for Reportable Segments" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.", "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]", "terseLabel": "Summary of Weighted-Average Assumptions and Health Care Cost Trend Rates Used to Determine Net Periodic Benefit Costs" } } }, "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r926" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Company's Income Before Expense (Benefit) for Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r30", "r31", "r32" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Components of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureInventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Summery of Pre-tax Amount and Locations of Derivative Instrument Net Gains (Losses) Recognized in the Condensed Consolidated Statement of Comprehensive Income" } } }, "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "terseLabel": "Summary of Performance Stock Unit Awards (PSUs) Activity" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule of Gross Sales to Customers Included in Reportable Segments and All Other Customers as a Group" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r99", "r100", "r102", "r111" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfTotalLongLivedAssetsByLocationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r590", "r592", "r594", "r595", "r596", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r618", "r619", "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedAndLongtermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2022RelativeTsrPsusDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Summary of Outstanding Stock Options" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r161", "r168", "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Estimated Fair Value of Converted Stock Options Using Hull-White Model in Binomial Lattice Option Pricing Framework" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Estimated Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r389", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r421", "r427", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r466", "r467", "r872", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r389", "r390", "r391", "r401", "r404", "r415", "r419", "r420", "r421", "r422", "r423", "r426", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment and Other Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSegmentAndOtherInformationSummaryOfTotalLongLivedAssetsByLocationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r405", "r406", "r407", "r408", "r409", "r410", "r424" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "Selling, General and Administrative Expense, Total" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative [Member]", "verboseLabel": "Selling, General and Administrative [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorLongTermNotes": { "auth_ref": [ "r40", "r896" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Senior Notes, Noncurrent", "terseLabel": "Long-term debt, net", "verboseLabel": "Senior notes" } } }, "localname": "SeniorLongTermNotes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesCurrent": { "auth_ref": [ "r37", "r896" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.", "label": "Senior Notes, Current", "terseLabel": "Long-term debt\u2014current portion" } } }, "localname": "SeniorNotesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Equity-settled share-based compensation", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r889" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Units, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant-Date Fair Value Per Unit, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted shares granted to purchase common stock", "verboseLabel": "Number of Units, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant-Date Fair Value Per Unit, Granted", "verboseLabel": "Weighted Average Grant-Date Fair Value Per Unit, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Units, Outstanding Ending Balance", "periodStartLabel": "Number of Units, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant-Date Fair Value Per Unit, Outstanding Ending Balance", "periodStartLabel": "Weighted Average Grant-Date Fair Value Per Unit, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Units, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r613" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total fair value of restricted stock units vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant-Date Fair Value Per Unit, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansWeightedAverageFairValuePerShareOfStockOptionAwardsGrantedAndAssumptionsUsedToValueStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Weighted average volatility", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedAndLongtermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2022RelativeTsrPsusDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansWeightedAverageFairValuePerShareOfStockOptionAwardsGrantedAndAssumptionsUsedToValueStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock price volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock price volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "verboseLabel": "Risk free rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedAndLongtermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2022RelativeTsrPsusDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansWeightedAverageFairValuePerShareOfStockOptionAwardsGrantedAndAssumptionsUsedToValueStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedAndLongtermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2022RelativeTsrPsusDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r162", "r164" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance", "terseLabel": "PSUs outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase to number of ordinary shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r891" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Common stock shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Common stock shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options, Exercisable as of December 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable as of December 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r613" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "verboseLabel": "Total intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Options, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Stock option granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value of converted stock options", "verboseLabel": "Weighted average fair value of options granted to purchase common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansWeightedAverageFairValuePerShareOfStockOptionAwardsGrantedAndAssumptionsUsedToValueStockOptionsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r175" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r598", "r599" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options, Outstanding Ending Balance", "periodStartLabel": "Options, Outstanding Beginning Balance", "terseLabel": "Share-based payment award options, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r598", "r599" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning Balance", "verboseLabel": "Options Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Incremental expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r594", "r595", "r596", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r618", "r619", "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedAndLongtermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2022RelativeTsrPsusDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Relative TSR PSUs [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Financial PSUs [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Strategic PSUs [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r597", "r616", "r617", "r618", "r619", "r622", "r634", "r635" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Range of Exercise Prices, Lower Range" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "periodEndLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Ending Balance", "periodStartLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Beginning Balance", "terseLabel": "Options Exercisable, Number Exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "periodEndLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance", "periodStartLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Beginning Balance", "terseLabel": "Options Outstanding, Number of options outstanding" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Range of Exercise Prices, Upper Range" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock price (closing stock price on March 14, 2021)", "verboseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureSharebasedAndLongtermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2022RelativeTsrPsusDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r1038" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of outstanding PSU award vesting amount range" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r623" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Total compensation cost", "totalLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount, Total" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r890" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Stock options contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Term to expiration" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansEstimatedFairValueOfConvertedStockOptionsUsingHullWhiteModelInBinomialLatticeOptionPricingFrameworkDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansWeightedAverageFairValuePerShareOfStockOptionAwardsGrantedAndAssumptionsUsedToValueStockOptionsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r175" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable as of December 31, 2022" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Contractual Term Remaining (in years) Exercisable as of December 31, 2022", "verboseLabel": "Options Exercisable, Weighted Average Remaining Contractual Term(in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Contractual Term Remaining (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Total fair value of stock options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options Exercisable, Weighted Average Exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options Outstanding, Weighted Average Remaining Contractual Term(in years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfOutstandingStockOptionsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r88", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentPropertyPlantAndEquipmentDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "U.S. State Tax [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r296", "r389", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r421", "r427", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r464", "r466", "r467", "r872", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r46", "r141", "r293", "r324", "r325", "r326", "r352", "r353", "r354", "r356", "r365", "r368", "r383", "r439", "r526", "r631", "r632", "r633", "r666", "r667", "r706", "r732", "r733", "r734", "r735", "r736", "r738", "r767", "r814", "r815", "r816" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Retained Earnings (Accumulated Deficit) [Member]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r352", "r353", "r354", "r383", "r780" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r23", "r24", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Assumed in acquisition", "verboseLabel": "Purchase of common stock shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r45", "r141", "r142", "r146", "r501" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Issuance of ordinary shares in conjunction with 2.5% Exchangeable Senior Notes due 2022, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r23", "r24", "r141", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of ordinary shares in conjunction with Employee Share Purchase Plan, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r23", "r24", "r141", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of ordinary shares - public offering, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r141", "r146" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Issuance of ordinary shares in conjunction with the exercise of stock options and the vesting of restricted stock and performance stock units, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r141", "r146", "r603" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r46", "r141", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of ordinary shares in conjunction with 2.5% Exchangeable Senior Notes due 2022" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r23", "r24", "r141", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of ordinary shares in conjunction with Employee Share Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r23", "r24", "r141", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of ordinary shares - public offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r23", "r24", "r141", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Issuance of ordinary shares in conjunction with the exercise of stock options and the vesting of restricted stock and performance stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r23", "r24", "r141", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Number of ordinary share repurchases" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r23", "r24", "r141", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase of ordinary shares", "terseLabel": "Total consideration" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r27", "r28", "r107", "r896", "r925", "r949", "r1077" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "SHAREHOLDERS\u2019 EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r149", "r339", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r697" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r739", "r770" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r739", "r770" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r739", "r770" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.", "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest", "terseLabel": "Cut off percentage for defining limited liability subsidiaries, portion of capital stock held maximum" } } }, "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareScheduleOfOutstandingSecuritiesExcludedFromComputationOfDilutedIncomePerOrdinaryShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary Sale Of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "auth_ref": [ "r180", "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "terseLabel": "Tax liabilities attributable to different corporations" } } }, "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "verboseLabel": "Income tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock, ordinary shares" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r44", "r147" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r44", "r147", "r148" ], "calculation": { "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, 384,366 ordinary shares at December 31, 2022 and December 31, 2021", "totalLabel": "Treasury Stock, Value, Total" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r355", "r356", "r357", "r358", "r369", "r431", "r432", "r436", "r437", "r438", "r439", "r440", "r441", "r631", "r632", "r633", "r664", "r665", "r666", "r667", "r683", "r684", "r685", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r742", "r743", "r747", "r748", "r749", "r750", "r762", "r763", "r764", "r765", "r766", "r767", "r782", "r783", "r784", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r1070" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r869", "r882", "r884", "r1094" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UndistributedEarningsOfDomesticSubsidiaries": { "auth_ref": [ "r638", "r677" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings of domestic subsidiaries or domestic joint ventures intended to be permanent.", "label": "Undistributed Earnings of Domestic Subsidiaries", "terseLabel": "Cumulative unremitted earnings" } } }, "localname": "UndistributedEarningsOfDomesticSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss": { "auth_ref": [ "r233" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective.", "label": "Unrealized Gain (Loss) on Interest Rate Cash Flow Hedges, Pretax, Accumulated Other Comprehensive Income (Loss)", "terseLabel": "Interest rate swap contracts designated as cash flow hedges" } } }, "localname": "UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r639", "r649" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance \u2013 uncertain tax positions", "periodStartLabel": "Beginning balance \u2013 uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesChangesInUncertainIncomeTaxPositionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": { "auth_ref": [ "r1065" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued", "terseLabel": "Uncertain tax position, penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r648" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Uncertain tax positions, interest and penalties included in deferred tax assets", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "terseLabel": "Tax positions in the year, Acquired uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesChangesInUncertainIncomeTaxPositionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "verboseLabel": "Tax positions in the year, Additions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesChangesInUncertainIncomeTaxPositionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r650" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Tax positions related to prior years, Additions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesChangesInUncertainIncomeTaxPositionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "auth_ref": [ "r1065" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense accrued for an underpayment of income taxes.", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "terseLabel": "Uncertain tax position, interest" } } }, "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r652" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Income tax penalties and interest expense" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r96", "r97", "r98", "r384", "r385", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r658" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase (decrease) in the deferred tax valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesAdjustments": { "auth_ref": [ "r934" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment", "terseLabel": "Adjustments relating to prior-year sales" } } }, "localname": "ValuationAllowancesAndReservesAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r345", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Total customer-related accruals and allowances" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Current provisions relating to sales", "verboseLabel": "Additions, Charged to costs and expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Payments relating to sales", "negatedTerseLabel": "Deductions from reserves" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r345", "r346", "r347", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebates", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesTables", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": { "auth_ref": [ "r931" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from business combination.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired", "terseLabel": "Viela acquisition" } } }, "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r345", "r346", "r347", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebates", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureAccruedTradeDiscountsAndRebatesTables", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureDerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VentureCapitalGainsLossesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on venture capital activities. Includes venture capital revenue, fair value adjustments, interest and dividends, investment gain (loss) and fee or other income from venture capital activities.", "label": "Venture Capital Gain (Loss), Net", "terseLabel": "Investment income" } } }, "localname": "VentureCapitalGainsLossesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r371", "r376" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average ordinary shares outstanding\u2014diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "verboseLabel": "Denominator - weighted average of ordinary shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r370", "r376" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average ordinary shares outstanding\u2014basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "verboseLabel": "Denominator - weighted average of ordinary shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.horizontherapeutics.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedNetIncomePerShareDetail", "http://www.horizontherapeutics.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1000": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1001": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1002": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1003": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1004": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1005": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1006": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1007": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1008": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1009": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1010": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1011": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1012": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1013": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1014": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1015": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1016": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1017": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1018": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1019": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1020": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1021": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1022": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1023": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1024": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1025": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1026": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1027": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1028": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1029": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1030": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1031": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1032": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1033": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1034": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1035": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1036": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1037": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1038": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1039": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1040": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1041": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1042": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1043": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1044": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1045": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1046": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1047": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1048": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1049": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1050": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1051": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1052": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1053": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1054": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1055": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1056": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1057": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1058": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1059": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1060": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1061": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1062": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1063": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1064": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1065": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1066": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1067": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1068": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1069": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1070": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1071": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1072": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1073": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1074": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1075": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1076": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1077": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1078": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1079": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1080": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123392319&loc=SL77920254-209983", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1081": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1082": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1083": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1084": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1085": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1086": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1087": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1088": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1089": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1090": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1091": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1092": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1093": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1094": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1095": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1096": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1097": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1098": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1099": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r11": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28511-109314", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28446-109314", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e845-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e848-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=25866437&loc=d3e10491-115837", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123392090&loc=d3e45424-112738", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28200-109314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "4EEEE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999725-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r845": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r846": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r847": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r848": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r849": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r851": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r852": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r853": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r854": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r855": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r903": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r904": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r905": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r906": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r907": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r908": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r909": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r911": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r912": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r964": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r965": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r966": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r967": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r968": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r969": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r970": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r971": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r972": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r973": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r974": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r975": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130611-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r976": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r977": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r978": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r979": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r980": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r981": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r982": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r983": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r984": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r985": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r986": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r987": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r988": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r989": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r990": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r991": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r992": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r993": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r994": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r995": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r996": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r997": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r998": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r999": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" } }, "version": "2.2" }